BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ;  European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-1713. [PMID: 15578508 DOI: 10.1053/j.gastro.2004.08.052] [Cited by in Crossref: 687] [Cited by in F6Publishing: 628] [Article Influence: 40.4] [Reference Citation Analysis]
Number Citing Articles
1 Campana L, Iredale J. Matrix Metalloproteinases and Their Inhibitors. Stellate Cells in Health and Disease. Elsevier; 2015. pp. 107-24. [DOI: 10.1016/b978-0-12-800134-9.00007-5] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
3 Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-Kafrawy S. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol. 2007;46:620-627. [PMID: 17316875 DOI: 10.1016/j.jhep.2006.12.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
4 Teixeira R, Marcos LA, Friedman SL. Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research 2007;37:579-95. [DOI: 10.1111/j.1872-034x.2007.00085.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Carloni V, Luong TV, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 2014;34:834-843. [PMID: 24397349 DOI: 10.1111/liv.12465] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
6 Jia J, Hou J, Ding H, Chen G, Xie Q, Wang Y, Zeng M, Zhao J, Wang T, Hu X, Schuppan D. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30:756-762. [PMID: 25353058 DOI: 10.1111/jgh.12840] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
7 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
8 Kelleher TB, Afdhal N. Noninvasive Assessment of Liver Fibrosis. Clinics in Liver Disease 2005;9:667-83. [DOI: 10.1016/j.cld.2005.08.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
9 Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol. 2015;13:772-9.e1-3. [PMID: 25528010 DOI: 10.1016/j.cgh.2014.12.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 12.9] [Reference Citation Analysis]
10 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131-160. [PMID: 19004189 DOI: 10.1016/s0065-2423(08)00404-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
11 Grizzi F, Russo C, Franceschini B, Rocco MD, Torri V, Morenghi E, Fassati LR, Dioguardi N. Sampling variability of computer-aided fractal-corrected measures of liver fibrosis in needle biopsy specimens. World J Gastroenterol 2006; 12(47): 7660-7665 [PMID: 17171796 DOI: 10.3748/wjg.v12.i47.7660] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
12 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 176] [Article Influence: 38.0] [Reference Citation Analysis]
13 Fernandes FF, Ferraz ML, Andrade LE, Dellavance A, Terra C, Pereira G, Pereira JL, Campos F, Figueiredo F, Perez RM. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients. J Clin Gastroenterol. 2015;49:235-241. [PMID: 24714186 DOI: 10.1097/mcg.0000000000000128] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
14 Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ, Sampaio JP, Medina-Pestana JO, Lanzoni VP, Silva AE, Ferraz ML. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008;15:666-74. [PMID: 18482283 DOI: 10.1111/j.1365-2893.2008.00992.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
15 Ding ZM, Xiao Y, Wu X, Zou H, Yang S, Shen Y, Xu J, Workman HC, Usborne AL, Hua H. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. Front Pharmacol. 2018;9:410. [PMID: 29765319 DOI: 10.3389/fphar.2018.00410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Gümüşay O, Ozenirler S, Atak A, Sönmez C, Ozkan S, Tuncel AF, Yılmaz G, Akyol G. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 2013;43:228-37. [PMID: 22734888 DOI: 10.1111/j.1872-034X.2012.01057.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
17 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
18 Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One. 2013;8:e59088. [PMID: 23555619 DOI: 10.1371/journal.pone.0059088.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Sanai FM, Keeffe EB. Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol. 2010;16:124-132. [PMID: 20339187 DOI: 10.4103/1319-3767.61244] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
20 Carpentier A, Conti F, Carrière M, Aoudjehane L, Miroux C, Moralès O, Calmus Y, Groux H, Auriault C, Pancré V, Delhem N, Podevin P. Analysis of gene transcription in sera during chronic hepatitis C infection. J Med Virol 2009;81:473-80. [PMID: 19152403 DOI: 10.1002/jmv.21398] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
21 Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, Heller T, Koh C. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2017;45:127-138. [PMID: 27813124 DOI: 10.1111/apt.13834] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
22 Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Bréchot MC. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:395-402. [PMID: 17156890 DOI: 10.1016/j.jhep.2006.09.020] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
23 Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 2012;29:1098-1107. [PMID: 22672330 DOI: 10.1111/j.1464-5491.2012.03732.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
24 Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L, Cross R, Degré D. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol. 2011;55:38-44. [PMID: 21145859 DOI: 10.1016/j.jhep.2010.10.018] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
25 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Reference Citation Analysis]
26 Guéchot J, Lasnier E, Sturm N, Paris A, Zarski JP. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta. 2010;411:86-91. [PMID: 19850017 DOI: 10.1016/j.cca.2009.10.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
27 Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20(25): 8018-8023 [PMID: 25009372 DOI: 10.3748/wjg.v20.i25.8018] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
28 Kim SG, Kim YS, Jung SW, Kim HK, Jang JY, Moon JH, Kim HS, Lee JS, Lee MS, Shim CS, Kim BS. The usefulness of transient elastography to diagnose cirrhosis in patients with alcoholic liver disease. Korean J Hepatol 2009;15:42. [DOI: 10.3350/kjhep.2009.15.1.42] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
29 Sebastiani G, Vario A, Guido M, Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat. 2008;15:212-218. [PMID: 18179453 DOI: 10.1111/j.1365-2893.2007.00932.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
30 Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006;21:1459-1465. [PMID: 16911693 DOI: 10.1111/j.1440-1746.2006.04447.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 40] [Article Influence: 0.8] [Reference Citation Analysis]
31 Marques S, Carmo J, Túlio MA, Bispo M, Matos L, Chagas C. Diagnostic Performance of Real-Time Elastography in the Assessment of Advanced Fibrosis in Chronic Hepatitis C. GE Port J Gastroenterol 2016;23:13-8. [PMID: 28868425 DOI: 10.1016/j.jpge.2015.10.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
32 Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-125. [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
33 Cholongitas E, Senzolo M, Standish R, Marelli L, Quaglia A, Patch D, Dhillon AP, Burroughs AK. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol. 2006;125:710-721. [PMID: 16707372 DOI: 10.1309/w3xcnt4hkfbn2g0b] [Cited by in Crossref: 151] [Cited by in F6Publishing: 4] [Article Influence: 9.4] [Reference Citation Analysis]
34 Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007;41:616-623. [PMID: 17577119 DOI: 10.1097/01.mcg.0000225642.90898.0e] [Cited by in Crossref: 135] [Cited by in F6Publishing: 127] [Article Influence: 9.0] [Reference Citation Analysis]
35 Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, Stuart KA, Brown NN, Saad N, Clouston A, Irvine KM, Russell AW, Valery PC, Williams S, Powell EE. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J 2018;48:144-51. [PMID: 29083080 DOI: 10.1111/imj.13667] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
36 Miele L, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res. 2009;154:194-201. [PMID: 19766963 DOI: 10.1016/j.trsl.2009.06.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
37 Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Review of Gastroenterology & Hepatology 2019;13:361-74. [DOI: 10.1080/17474124.2019.1579641] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
38 Yan L, Deng Y, Zhou J, Zhao H, Wang G; China HepB-Related Fibrosis Assessment Research Group. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. Infection 2018;46:385-93. [PMID: 29600444 DOI: 10.1007/s15010-018-1136-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
39 Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim Biophys Acta. 2013;1832:876-883. [PMID: 23149387 DOI: 10.1016/j.bbadis.2012.11.002] [Cited by in Crossref: 146] [Cited by in F6Publishing: 134] [Article Influence: 14.6] [Reference Citation Analysis]
40 Kim SU, Ahn SH, Park JY, Kang W, Kim do Y, Park YN, Chon CY, Han KH. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol. 2009;43:267-271. [PMID: 18987556 DOI: 10.1097/mcg.0b013e31816f212e] [Cited by in Crossref: 51] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
41 Ebrahimi H, Naderian M, Sohrabpour AA. New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis. 2016;8:166-178. [PMID: 27698966 DOI: 10.15171/mejdd.2016.29] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
42 Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, Segovia-silvestre T, Zhang C, Zheng Q, Sun S, Cao Y, Barkholt V, Hägglund P, Bay-jensen A, Qvist P, Karsdal M. A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011;16:616-28. [DOI: 10.3109/1354750x.2011.620628] [Cited by in Crossref: 106] [Cited by in F6Publishing: 59] [Article Influence: 9.6] [Reference Citation Analysis]
43 Frankowski M, Świerkot J, Gomułkiewicz M, Korman L, Skoczyńska M, Starba A. Usefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. Rheumatol Int 2021. [PMID: 34870735 DOI: 10.1007/s00296-021-05059-z] [Reference Citation Analysis]
44 Snyder N, Nguyen A, Gajula L, Soloway R, Xiao SY, Lau DT, Petersen J. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta. 2007;381:119-123. [PMID: 17442291 DOI: 10.1016/j.cca.2007.02.046] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
45 Zeng DB, Di L, Zhang RC, Guo QL, Duan BW, Jia CY, Chen F, Lin DD, Zang YJ, Lu SC. The Effect of Splenectomy on the Reversal of Cirrhosis: a Prospective Study. Gastroenterol Res Pract. 2019;2019:5459427. [PMID: 31093275 DOI: 10.1155/2019/5459427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Mauro E, Crespo G, Montironi C, Londoño M, Hernández-gea V, Ruiz P, Sastre L, Lombardo J, Mariño Z, Díaz A, Colmenero J, Rimola A, Garcia-pagán JC, Brunet M, Forns X, Navasa M. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C: Mauro et al. Hepatology 2018;67:1683-94. [DOI: 10.1002/hep.29557] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 16.5] [Reference Citation Analysis]
47 Kim SU, Han KH, Park JY, Ahn SH, Chung MJ, Chon CY, Choi EH, Kim DY. Liver stiffness measurement using FibroScan is influenced by serum total bilirubin in acute hepatitis. Liver Int. 2009;29:810-815. [PMID: 19018979 DOI: 10.1111/j.1478-3231.2008.01894.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
48 Simbrunner B, Marculescu R, Scheiner B, Schwabl P, Bucsics T, Stadlmann A, Bauer DJM, Paternostro R, Eigenbauer E, Pinter M, Stättermayer AF, Trauner M, Mandorfer M, Reiberger T. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int 2020;40:1713-24. [PMID: 32358998 DOI: 10.1111/liv.14498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, Andersen IM, Naess S, Thorburn D, Saffioti F, Vatn M, Gilja OH, Lund-Johansen F, Syversveen T, Brabrand K, Parés A, Ponsioen CY, Pinzani M, Färkkilä M, Moum B, Ueland T, Røsjø H, Rosenberg W, Boberg KM, Karlsen TH. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology 2015;62:188-97. [PMID: 25833813 DOI: 10.1002/hep.27825] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 10.4] [Reference Citation Analysis]
50 Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M;  ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56:55-62. [PMID: 21781944 DOI: 10.1016/j.jhep.2011.05.024] [Cited by in Crossref: 142] [Cited by in F6Publishing: 126] [Article Influence: 12.9] [Reference Citation Analysis]
51 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
52 Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34:674-679. [PMID: 19195629 DOI: 10.1016/s1262-3636(08)74603-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
53 Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time. Am J Gastroenterol. 2005;100:1981-1983. [PMID: 16128942 DOI: 10.1111/j.1572-0241.2005.00284.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
54 Shin WG, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, Kim DJ, Jun SY, Park CK. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis. 2008;40:267-274. [PMID: 18055281 DOI: 10.1016/j.dld.2007.10.011] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 6.7] [Reference Citation Analysis]
55 Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-López R, Castellano-Megias VM, Nevado-Santos M, Alcón JC. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology. 2008;47:810-816. [PMID: 18098299 DOI: 10.1002/hep.22112] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
56 Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-1873. [PMID: 16055434 DOI: 10.1373/clinchem.2005.048389] [Cited by in Crossref: 362] [Cited by in F6Publishing: 330] [Article Influence: 21.3] [Reference Citation Analysis]
57 Ingegnoli F, Gualtierotti R, Schioppo T, Orenti A, Boracchi P, Lubatti C, Mastaglio C, Galbiati V, Murgo A, Zeni S, Grossi C, Borghi O, Rosenberg W, Castelnovo L, Meroni Pier L. Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon? Ann Rheum Dis 2014;73:940-1. [PMID: 24344159 DOI: 10.1136/annrheumdis-2013-204009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Forns X. Diagnosis of liver fibrosis in 2008. Gastroentérologie Clinique et Biologique 2008;32:1-3. [DOI: 10.1016/s0399-8320(08)73988-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-lyon I, Williams R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. European Journal of Gastroenterology & Hepatology 2010;22:474-80. [DOI: 10.1097/meg.0b013e328332dd0a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
60 Alexander J, Kowdley KV. Hereditary Hemochromatosis: Genetics, Pathogenesis, and Clinical Management. Annals of Hepatology 2005;4:240-7. [DOI: 10.1016/s1665-2681(19)32046-0] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
61 Hartley JL, Brown RM, Tybulewicz A, Hayes P, Wilson DC, Gillett P, McKiernan P. Hyaluronic acid predicts hepatic fibrosis in children with hepatic disease. J Pediatr Gastroenterol Nutr. 2006;43:217-221. [PMID: 16877988 DOI: 10.1097/01.mpg.0000228121.44606.9f] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
62 Fragkos KC, Picasso Bouroncle MC, Kumar S, Caselton L, Menys A, Bainbridge A, Taylor SA, Torrealdea F, Kumagai T, Di Caro S, Rahman F, Macnaughtan J, Chouhan MD, Mehta S. Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study. Nutrients 2020;12:E2151. [PMID: 32707726 DOI: 10.3390/nu12072151] [Reference Citation Analysis]
63 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 17.7] [Reference Citation Analysis]
64 Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020;73:252-62. [DOI: 10.1016/j.jhep.2020.03.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
65 Pinzani M. Non-invasive evaluation of hepatic fibrosis: don’t count your chickens before they’re hatched. Gut. 2006;55:310-312. [PMID: 16474104 DOI: 10.1136/gut.2005.068585] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
66 Athwal VS, Pritchett J, Martin K, Llewellyn J, Scott J, Harvey E, Zaitoun AM, Mullan AF, Zeef LAH, Friedman SL, Irving WL, Hanley NA, Guha IN, Piper Hanley K. SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis. Sci Rep 2018;8:17905. [PMID: 30559459 DOI: 10.1038/s41598-018-36037-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
67 Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549-1557. [PMID: 18846542 DOI: 10.1002/hep.22517] [Cited by in Crossref: 134] [Cited by in F6Publishing: 127] [Article Influence: 9.6] [Reference Citation Analysis]
68 Rosenberg WM, Tanwar S, Trembling P. Complexities of HCV management in the new era of direct-acting antiviral agents. QJM 2014;107:17-9. [PMID: 24065837 DOI: 10.1093/qjmed/hct181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
69 Saiz de la Hoya-zamácola P, Marco-mouriño A, Clemente-ricote G, Portilla-sogorb J, Boix-martínez V, Núñez-martínez Ó, Reus-bañuls S, Teixidó i Pérez N. Recomendaciones de expertos sobre el diagnóstico y tratamiento de la hepatitis C crónica en el medio penitenciario. Gastroenterología y Hepatología 2006;29:551-9. [DOI: 10.1157/13094351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
70 Munsterman ID, Duijnhouwer AL, Kendall TJ, Bronkhorst CM, Ronot M, van Wettere M, van Dijk APJ, Drenth JPH, Tjwa ETTL, van Dijk APJ, Drenth JPH, Duijnhouwer AL, van Kimmenade RRJ, van Koeverden SW, Munsterman ID, Tanke RB, Tjwa ETTL, Udink ten Cate FEA; Nijmegen Fontan Initiative. The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort. European Heart Journal 2019;40:1057-68. [DOI: 10.1093/eurheartj/ehy620] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
71 Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, Kittner JM, Weyer V, Knapstein J, Schattenberg JM, Wörns MA, Galle PR, Zimmermann T. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Digestive and Liver Disease 2016;48:291-7. [DOI: 10.1016/j.dld.2015.09.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
72 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
73 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2006. pp. 87-109. [DOI: 10.1016/b978-1-4160-3258-8.50011-5] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
74 Kaji H, Ocho M, Togayachi A, Kuno A, Sogabe M, Ohkura T, Nozaki H, Angata T, Chiba Y, Ozaki H, Hirabayashi J, Tanaka Y, Mizokami M, Ikehara Y, Narimatsu H. Glycoproteomic Discovery of Serological Biomarker Candidates for HCV/HBV Infection-Associated Liver Fibrosis and Hepatocellular Carcinoma. J Proteome Res 2013;12:2630-40. [DOI: 10.1021/pr301217b] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
75 Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease: REVIEW: PAEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE. Alimentary Pharmacology & Therapeutics 2008;28:13-24. [DOI: 10.1111/j.1365-2036.2008.03703.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
76 Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009;7:219-226. [PMID: 19068241 DOI: 10.1016/j.cgh.2008.10.034] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
77 Bissell DM. Assessing fibrosis without a liver biopsy: are we there yet. Gastroenterology. 2004;127:1847-1849. [PMID: 15578524 DOI: 10.1053/j.gastro.2004.10.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
78 Wang Y, Yuan JM, Pan A, Koh WP. Tissue inhibitor matrix metalloproteinase 1 and risk of type 2 diabetes in a Chinese population. BMJ Open Diabetes Res Care 2020;8:e001051. [PMID: 32303531 DOI: 10.1136/bmjdrc-2019-001051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
80 Agrawal S, Hoad CL, Francis ST, Guha IN, Kaye P, Aithal GP. Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. Scandinavian Journal of Gastroenterology 2017;52:107-15. [DOI: 10.1080/00365521.2016.1233578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
81 Suehiro Y, Tachikawa Y, Abe Y, Ohshima K, Muta K, Tani K. Epithelioid hemangioendothelioma presenting with severe myelofibrosis and a high serum hyaluronan level. Eur J Haematol 2007;79:349-53. [DOI: 10.1111/j.1600-0609.2007.00909.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Duarte-rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Annals of Hepatology 2012;11:426-39. [DOI: 10.1016/s1665-2681(19)31456-5] [Cited by in Crossref: 31] [Article Influence: 3.1] [Reference Citation Analysis]
83 Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:666-75. [PMID: 24061203 DOI: 10.1038/nrgastro.2013.175] [Cited by in Crossref: 168] [Cited by in F6Publishing: 146] [Article Influence: 18.7] [Reference Citation Analysis]
84 Siddiqui MS, Patidar KR, Boyett S, Luketic VA, Puri P, Sanyal AJ. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2016;36:572-9. [PMID: 26713759 DOI: 10.1111/liv.13054] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
85 Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Practice & Research Clinical Gastroenterology 2011;25:231-44. [DOI: 10.1016/j.bpg.2011.02.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
86 Catanzaro R, Milazzo M, Arona S, Sapienza C, Vasta D, Arcoria D, Marotta F. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 2013;12:500-507. [PMID: 24103280 DOI: 10.1016/s1499-3872(13)60079-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
87 Lubner MG, Pickhardt PJ. Multidetector Computed Tomography for Retrospective, Noninvasive Staging of Liver Fibrosis. Gastroenterol Clin North Am 2018;47:569-84. [PMID: 30115438 DOI: 10.1016/j.gtc.2018.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
88 Sporea I, Sirli R, Bota S, Popescu A, Sendroiu M, Jurchis A. Comparative study concerning the value of acoustic radiation force impulse elastography (ARFI) in comparison with transient elastography (TE) for the assessment of liver fibrosis in patients with chronic hepatitis B and C. Ultrasound Med Biol. 2012;38:1310-1316. [PMID: 22698510 DOI: 10.1016/j.ultrasmedbio.2012.03.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
89 Amarapurkar D, Amarapurkar A. Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis. J Clin Exp Hepatol 2015;5:314-9. [PMID: 26900273 DOI: 10.1016/j.jceh.2015.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
90 Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, Bataller R, Borhani AA, Duarte-Rojo A. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:31. [PMID: 32258535 DOI: 10.21037/tgh.2019.11.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
91 Zarski J, Bedossa P, Bronowicki J, Doffoel M, Poynard T. Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l’hépatite C. Gastroentérologie Clinique et Biologique 2007;31:34-9. [DOI: 10.1016/s0399-8320(07)92561-0] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
92 Adams LA, Angulo P. Role of Liver Biopsy and Serum Markers of Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease 2007;11:25-35. [DOI: 10.1016/j.cld.2007.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
93 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
94 Sogni P, Salmon-céron D, Podevin P. Prise en charge des complications de la cirrhose chez les patients VIH co-infectés par une hépatite virale B ou C. La Presse Médicale 2005;34:1579-83. [DOI: 10.1016/s0755-4982(05)84228-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
95 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007;381:107-113. [PMID: 17399697 DOI: 10.1016/j.cca.2007.02.038] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 8.8] [Reference Citation Analysis]
96 Cui XW, Friedrich-Rust M, Molo CD, Ignee A, Schreiber-Dietrich D, Dietrich CF. Liver elastography, comments on EFSUMB elastography guidelines 2013. World J Gastroenterol 2013; 19(38): 6329-6347 [PMID: 24151351 DOI: 10.3748/wjg.v19.i38.6329] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
97 Saiz de la Hoya-Zamácola P, Marco-Mouriño A, Clemente-Ricote G, Portilla-Sogorb J, Boix-Martínez V, Núñez-Martínez O, Reus-Bañuls S, Teixidó i Pérez N. [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. Enferm Infecc Microbiol Clin 2006;24:568-75. [PMID: 17125677 DOI: 10.1157/13093878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
98 Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411:1009-1017. [PMID: 20399764 DOI: 10.1016/j.cca.2010.04.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
99 Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One 2013;8:e59088. [PMID: 23555619 DOI: 10.1371/journal.pone.0059088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
100 Marshall RP, Simpson JK, Lukey PT. Strategies for biomarker discovery in fibrotic disease. Biochim Biophys Acta 2013;1832:1079-87. [PMID: 23376113 DOI: 10.1016/j.bbadis.2013.01.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
101 Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011;40:332-43. [DOI: 10.1007/s12020-011-9530-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
102 Hadefi A, Degré D, Trépo E, Moreno C. Noninvasive diagnosis in alcohol-related liver disease. Health Sci Rep 2020;3:e146. [PMID: 32166191 DOI: 10.1002/hsr2.146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
103 Karsdal MA, Genovese F, Madsen EA, Manon-jensen T, Schuppan D. Collagen and tissue turnover as a function of age: Implications for fibrosis. Journal of Hepatology 2016;64:103-9. [DOI: 10.1016/j.jhep.2015.08.014] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
104 Ydreborg M, Lisovskaja V, Lagging M, Brehm Christensen P, Langeland N, Buhl MR, Pedersen C, Mørch K, Wejstål R, Norkrans G, Lindh M, Färkkilä M, Westin J. A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLoS One 2014;9:e93601. [PMID: 24699777 DOI: 10.1371/journal.pone.0093601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
105 Cobbold JFL, Patel D, Taylor-robinson SD. Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques: Imaging in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2012;27:1281-92. [DOI: 10.1111/j.1440-1746.2012.07127.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
106 Park SH, Kim CH, Kim DJ, Suk KT, Park JH, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Park HY, Kim YB. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C. Clinical Biochemistry 2011;44:1396-9. [DOI: 10.1016/j.clinbiochem.2011.08.1151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
107 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708. [PMID: 20955971 DOI: 10.1016/j.bpg.2010.08.005] [Cited by in Crossref: 128] [Cited by in F6Publishing: 115] [Article Influence: 11.6] [Reference Citation Analysis]
108 Enomoto M, Morikawa H, Tamori A, Kawada N. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2014; 20(34): 12031-12038 [PMID: 25232240 DOI: 10.3748/wjg.v20.i34.12031] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
109 Suzuki T, Yamada A, Komatsu D, Kurozumi M, Fujinaga Y, Ueda K, Miyagawa S, Kadoya M. Evaluation of splenic perfusion and spleen size using dynamic computed tomography: Usefulness in assessing degree of liver fibrosis: Dynamic CT for assessing degree of liver fibrosis. Hepatol Res 2018;48:87-93. [DOI: 10.1111/hepr.12900] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
110 Bedossa P, Paradis V, Zucman-rossi J. Cellular and Molecular Techniques. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 88-110. [DOI: 10.1016/b978-0-7020-6697-9.00002-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
111 European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399-420. [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004] [Cited by in Crossref: 400] [Cited by in F6Publishing: 351] [Article Influence: 40.0] [Reference Citation Analysis]
112 Yoshioka K, Hashimoto S. Can non-invasive assessment of liver fibrosis replace liver biopsy? Hepatol Res 2012;42:233-40. [PMID: 22151829 DOI: 10.1111/j.1872-034X.2011.00928.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
113 Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008;38:762-9. [PMID: 18462378 DOI: 10.1111/j.1872-034X.2008.00364.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
114 Nana J, Skaare K, Bosson JL, Leroy V, Asselah T, Adler M, Sturm N, Zarski JP. EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with hepatitis B: An independent validation. J Viral Hepat 2021;28:1169-76. [PMID: 34002927 DOI: 10.1111/jvh.13548] [Reference Citation Analysis]
115 Cho HJ, Kim SS, Ahn SJ, Bae CB, Kim HG, Kim YJ, Lee SK, Song GW, Kim DJ, Hwang SG, Yang JM, Kim YB, Park YN, Cho SW, Cheong JY. Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B. Clin Biochem 2012;45:1564-7. [PMID: 22885475 DOI: 10.1016/j.clinbiochem.2012.07.107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
116 Sangwaiya MJ, Sherman DI, Lomas DJ, Shorvon PJ. Latest developments in the imaging of fibrotic liver disease. Acta Radiol. 2014;55:802-813. [PMID: 24226293 DOI: 10.1177/0284185113510159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
117 Moon KM, Kim G, Baik SK, Choi E, Kim MY, Kim HA, Cho MY, Shin SY, Kim JM, Park HJ. Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. Clin Mol Hepatol. 2013;19:389-398. [PMID: 24459644 DOI: 10.3350/cmh.2013.19.4.3890] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Long KB, Li Z, Burgwin CM, Choe SG, Martyanov V, Sassi-Gaha S, Earl JP, Eutsey RA, Ahmed A, Ehrlich GD, Artlett CM, Whitfield ML, Blankenhorn EP. The Tsk2/+ mouse fibrotic phenotype is due to a gain-of-function mutation in the PIIINP segment of the Col3a1 gene. J Invest Dermatol 2015;135:718-27. [PMID: 25330296 DOI: 10.1038/jid.2014.455] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
119 Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306. [DOI: 10.1002/hep.21520] [Cited by in Crossref: 168] [Cited by in F6Publishing: 159] [Article Influence: 11.2] [Reference Citation Analysis]
120 Connoy A, Turner J, Núñez M. Levels of Serum Markers of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis C Virus Infection According to HIV Status and Antiretroviral Use. AIDS Research and Human Retroviruses 2011;27:719-25. [DOI: 10.1089/aid.2010.0224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
121 Carrión JA, Torres F, Crespo G, Miquel R, García-valdecasas J, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010;51:23-34. [DOI: 10.1002/hep.23240] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
122 Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis 2020;21:127-38. [PMID: 32108989 DOI: 10.1111/1751-2980.12854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
123 Vizzutti; F, Arena; U, Nobili; V, Tarquini; R, Trappoliere; M, Laffi; G, Marra; F, Pinzani M. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology 2009;8:89-94. [DOI: 10.1016/s1665-2681(19)31784-3] [Cited by in Crossref: 30] [Article Influence: 2.3] [Reference Citation Analysis]
124 Valenti L, Dongiovanni P. Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. Transl Res 2010;156:226-8. [PMID: 20875898 DOI: 10.1016/j.trsl.2010.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
125 Peters MG, Bacchetti P, Boylan R, French AL, Tien PC, Plankey MW, Glesby MJ, Augenbraun M, Golub ET, Karim R, Parkes J, Rosenberg W. Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. AIDS 2016;30:723-9. [PMID: 26595542 DOI: 10.1097/QAD.0000000000000975] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
126 Crockett SD, Kaltenbach T, Keeffe EB. Do We Still Need a Liver Biopsy? Are the Serum Fibrosis Tests Ready for Prime Time? Clinics in Liver Disease 2006;10:513-34. [DOI: 10.1016/j.cld.2006.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
127 Voutilainen SH, Kosola SK, Tervahartiala TI, Sorsa TA, Jalanko HJ, Pakarinen MP. Liver and serum expression of matrix metalloproteinases in asymptomatic pediatric liver transplant recipients. Transpl Int 2017;30:124-33. [DOI: 10.1111/tri.12879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
128 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
129 Yoo EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han K, Chon CY, Kim H. Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea. Liver Int 2013;33:706-13. [DOI: 10.1111/liv.12136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
130 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
131 Wasmuth H, Trautwein C. Leberfibrose: Klinik, Diagnostik und Management. Internist 2010;51:14-20. [DOI: 10.1007/s00108-009-2409-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
132 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
133 Henry ZH, Argo CK. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Gastroenterology Clinics of North America 2020;49:45-62. [DOI: 10.1016/j.gtc.2019.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R. A Simple Approach to Noninvasively Identifying Significant Fibrosis in Chronic Hepatitis C Patients in Clinical Practice: . Journal of Clinical Gastroenterology 2006;40:521-7. [DOI: 10.1097/00004836-200607000-00011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
135 Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012;6:379-85. [PMID: 21557024 DOI: 10.1007/s12072-011-9277-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 6.5] [Reference Citation Analysis]
136 Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009;7:397-414; quiz 366. [PMID: 19114127 DOI: 10.1016/j.cgh.2008.11.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
137 Dhyani M, Anvari A, Samir AE. Ultrasound elastography: liver. Abdom Imaging 2015;40:698-708. [PMID: 25690689 DOI: 10.1007/s00261-015-0373-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
138 Pinzani M, Kowdley K, Mccaughan G, Trautwein C. Noninvasive methods for the assessment of liver fibrosis: A window open on the future? Hepatology 2011;54:1476-7. [DOI: 10.1002/hep.24584] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
139 Sethi S, Simonetto DA, Abdelmoneim SS, Campion MB, Kaloiani I, Clayton AC, Kremers WK, Halling KC, Kamath PS, Talwalkar J, Shah VH. Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol 2012;2:19-26. [PMID: 25755402 DOI: 10.1016/S0973-6883(12)60078-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
140 Scott R, Guha IN. Non-invasive monitoring of liver fibrosis. British Medical Bulletin 2014;112:97-106. [DOI: 10.1093/bmb/ldu031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
141 Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2013;7:356-68. [PMID: 26201770 DOI: 10.1007/s12072-013-9439-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
142 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854. [PMID: 17393509 DOI: 10.1002/hep.21496] [Cited by in Crossref: 1507] [Cited by in F6Publishing: 1351] [Article Influence: 100.5] [Reference Citation Analysis]
143 Tural C, Tor J, Sanvisens A, Pérez-Alvarez N, Martínez E, Ojanguren I, García-Samaniego J, Rockstroh J, Barluenga E, Muga R, Planas R, Sirera G, Rey-Joly C, Clotet B. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009;7:339-45. [PMID: 19171202 DOI: 10.1016/j.cgh.2008.11.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
144 Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006;43:S113-20. [DOI: 10.1002/hep.21046] [Cited by in Crossref: 221] [Cited by in F6Publishing: 210] [Article Influence: 13.8] [Reference Citation Analysis]
145 Karanjia RN, Crossey MME, Cox IJ, Fye HKS, Njie R, Goldin RD, Taylor-Robinson SD. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol 2016; 22(45): 9880-9897 [PMID: 28018096 DOI: 10.3748/wjg.v22.i45.9880] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
146 De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol 2018;9:115-21. [PMID: 29588839 DOI: 10.1136/flgastro-2017-100865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
147 Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010;59:1401-1409. [PMID: 20675691 DOI: 10.1136/gut.2010.207423.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-360. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in Crossref: 172] [Cited by in F6Publishing: 150] [Article Influence: 43.0] [Reference Citation Analysis]
149 Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(24): 7427-7435 [PMID: 26139988 DOI: 10.3748/wjg.v21.i24.7427] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
150 Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-314. [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
151 Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, Herold CJ, Bashir MR, Van Beers BE. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging. 2017;45:646-659. [PMID: 27862590 DOI: 10.1002/jmri.25518] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
152 Zou X, Chi X, Pan Y, Du D, Sun H, Matsuda A, Li W, Kuno A, Zhang X, Narimatsu H, Niu J, Zhang Y. LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. Clin Proteomics 2014;11:44. [PMID: 25593566 DOI: 10.1186/1559-0275-11-44] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
153 Baldo DC, Dellavance A, Ferraz MLG, Andrade LEC. Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Auto Immun Highlights 2019;10:10. [PMID: 32257066 DOI: 10.1186/s13317-019-0120-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20(45): 16820-16830 [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 67] [Article Influence: 11.6] [Reference Citation Analysis]
155 Amara S, Lopez K, Banan B, Brown SK, Whalen M, Myles E, Ivy MT, Johnson T, Schey KL, Tiriveedhi V. Synergistic effect of pro-inflammatory TNFα and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis. Mol Immunol 2015;64:26-35. [PMID: 25467797 DOI: 10.1016/j.molimm.2014.10.021] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
156 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
157 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007;11:1031-1051. [PMID: 17979881 DOI: 10.1111/j.1582-4934.2007.00092.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
158 Zeng DW, Dong J, Jiang JJ, Zhu YY, Liu YR. Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase. World J Gastroenterol 2016; 22(43): 9586-9594 [PMID: 27920479 DOI: 10.3748/wjg.v22.i43.9586] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
159 Afdhal NH, Curry M. Technology evaluation: a critical step in the clinical utilization of novel diagnostic tests for liver fibrosis. J Hepatol. 2007;46:543-545. [PMID: 17316879 DOI: 10.1016/j.jhep.2007.01.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
160 Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Rev Gastroenterol Hepatol 2008;5:95-106. [DOI: 10.1038/ncpgasthep1025] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 8.8] [Reference Citation Analysis]
161 Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006;55:569-78. [PMID: 16531536 DOI: 10.1136/gut.2005.084475] [Cited by in Crossref: 275] [Cited by in F6Publishing: 246] [Article Influence: 17.2] [Reference Citation Analysis]
162 Corpechot C. Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases. Clin Liver Dis 2016;20:143-58. [PMID: 26593296 DOI: 10.1016/j.cld.2015.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
163 Karsdal MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, Surabattula R, Villesen IF, Luo Y, Shevell D, Gudmann NS, Nielsen MJ, George J, Christian R, Leeming DJ, Schuppan D. Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int. 2020;40:736-750. [PMID: 31997561 DOI: 10.1111/liv.14390] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
164 Berk PD. An editor's look-back. Hepatology 2006;43:S13-30. [PMID: 16447279 DOI: 10.1002/hep.21056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
165 Tien PC, Duarte M, Roque A, Price J. MRE and ELF in Liver Fibrosis Assessment: Are Two Better Than One? Dig Dis Sci 2020;65:928-30. [DOI: 10.1007/s10620-019-05923-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
166 Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression. Future Sci OA 2018;4:FSO250. [PMID: 29255622 DOI: 10.4155/fsoa-2017-0083] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
167 Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol 2014; 20(48): 18131-18150 [PMID: 25561782 DOI: 10.3748/wjg.v20.i48.18131] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
168 Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:85-91. [PMID: 23451000 DOI: 10.3238/arztebl.2013.0085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
169 Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C. Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2008;32:858-65. [DOI: 10.1016/j.gcb.2008.05.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
170 Day J, Patel P, Parkes J, Rosenberg W. Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. J Appl Lab Med. 2019;3:815-826. [PMID: 31639756 DOI: 10.1373/jalm.2018.027359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
171 Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, Garg H, Chandan Kumar KN, Bihari C, Sarin SK. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2013;58:265-74. [PMID: 22790906 DOI: 10.1007/s10620-012-2306-1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
172 Hwang HW, Yu JH, Jin YJ, Suh YJ, Lee JW. Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker. Medicine (Baltimore) 2020;99:e21162. [PMID: 32664153 DOI: 10.1097/MD.0000000000021162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: Are they ready for prime time in the management of HIV/HCV co-infected patients? Journal of Hepatology 2005;43:2-5. [DOI: 10.1016/j.jhep.2005.05.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
174 Oliveira AC, Reber M, Lanzoni V, Ferraz ML, Parise ER. Teste respiratório da 13C-metacetina na doença hepática crônica pelo vírus C. Arq Gastroenterol 2006;43:41-4. [DOI: 10.1590/s0004-28032006000100011] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
175 Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008;62:1056-1062. [PMID: 17537188 DOI: 10.1111/j.1742-1241.2007.01368.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
176 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
177 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
178 Zaman BA, Rasool SO, Merza MA, Abdulah DM. Hepcidin-to-ferritin ratio: A potential novel index to predict iron overload-liver fibrosis in ß-thalassemia major. Transfus Clin Biol 2021:S1246-7820(21)00521-8. [PMID: 34856399 DOI: 10.1016/j.tracli.2021.11.001] [Reference Citation Analysis]
179 Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18(39): 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
180 Fuchs BC, Wang H, Yang Y, Wei L, Polasek M, Schühle DT, Lauwers GY, Parkar A, Sinskey AJ, Tanabe KK, Caravan P. Molecular MRI of collagen to diagnose and stage liver fibrosis. J Hepatol 2013;59:992-8. [PMID: 23838178 DOI: 10.1016/j.jhep.2013.06.026] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 10.4] [Reference Citation Analysis]
181 Abignano G, Blagojevic J, Bissell LA, Dumitru RB, Eng S, Allanore Y, Avouac J, Bosello S, Denton CP, Distler O, Ferraccioli G, Jordan S, Matucci-Cerinic M, Ong V, Messenger M, Hutchinson M, Buch MH, Emery P, Del Galdo F. European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. Rheumatology (Oxford) 2019;58:254-9. [PMID: 30239834 DOI: 10.1093/rheumatology/key271] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
182 Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology. 2008;134:1670-1681. [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001] [Cited by in Crossref: 289] [Cited by in F6Publishing: 271] [Article Influence: 20.6] [Reference Citation Analysis]
183 Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, Mccabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, Mckane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants Appl Res 2018;6:1-528. [DOI: 10.3310/pgfar06030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
184 Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. Journal of Digestive Diseases 2009;10:7-14. [DOI: 10.1111/j.1751-2980.2008.00356.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
185 Du D, Zhu X, Kuno A, Matsuda A, Tsuruno C, Yu D, Zhang Y, Ikehara Y, Tanaka Y, Zhang X. Comparison of LecT-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels. Clin Chim Acta. 2012;413:1796-1799. [PMID: 22796373 DOI: 10.1016/j.cca.2012.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
186 Burroughs AK, Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results? J Hepatol. 2007;46:751-755. [PMID: 17383047 DOI: 10.1016/j.jhep.2007.02.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
187 Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis. 2012;16:567-585. [PMID: 22824481 DOI: 10.1016/j.cld.2012.05.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
188 Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Harris S, Menon U, Rosenberg WM. The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. BMC Gastroenterol 2020;20:104. [PMID: 32293289 DOI: 10.1186/s12876-020-01251-w] [Reference Citation Analysis]
189 D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One 2016;11:e0155967. [PMID: 27304619 DOI: 10.1371/journal.pone.0155967] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
190 Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol. 2005;43:78-84. [PMID: 15894397 DOI: 10.1016/j.jhep.2005.02.025] [Cited by in Crossref: 153] [Cited by in F6Publishing: 132] [Article Influence: 9.0] [Reference Citation Analysis]
191 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
192 Ismail MH, Pinzani M. Reversal of liver fibrosis. Saudi J Gastroenterol. 2009;15:72-79. [PMID: 19568569 DOI: 10.4103/1319-3767.45072] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
193 Patel V, Sanyal AJ, Sterling R. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016;20:277-292. [PMID: 27063269 DOI: 10.1016/j.cld.2015.10.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
194 Vergniol J, de Ledinghen V. Diagnostic non invasif de la fibrose hépatique : modalités pratiques d’utilisation des marqueurs sanguins et du FibroScan. Gastroentérologie Clinique et Biologique 2009;33:334-44. [DOI: 10.1016/j.gcb.2009.02.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
195 Chung RT. Assessment of efficacy of treatment in HCV: Infection and disease. Journal of Hepatology 2006;44:S56-9. [DOI: 10.1016/j.jhep.2005.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
196 Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2016; 22(29): 6663-6672 [PMID: 27547009 DOI: 10.3748/wjg.v22.i29.6663] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
197 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
198 Boukli NM, Shetty V, Cubano L, Ricaurte M, Coelho-Dos-Reis J, Nickens Z, Shah P, Talal AH, Philip R, Jain P. Unique and differential protein signatures within the mononuclear cells of HIV-1 and HCV mono-infected and co-infected patients. Clin Proteomics. 2012;9:11. [PMID: 22958358 DOI: 10.1186/1559-0275-9-11] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
199 Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-335. [PMID: 21254180 DOI: 10.1002/hep.24013] [Cited by in Crossref: 272] [Cited by in F6Publishing: 248] [Article Influence: 22.7] [Reference Citation Analysis]
200 Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T;  LIDO Study Group;  CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. [PMID: 16503961 DOI: 10.1186/1471-230x-6-6] [Cited by in Crossref: 290] [Cited by in F6Publishing: 110] [Article Influence: 18.1] [Reference Citation Analysis]
201 Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol 2008; 14(21): 3396-3402 [PMID: 18528937 DOI: 10.3748/wjg.14.3396] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
202 Kuwashiro T, Takahashi H, Hyogo H, Ogawa Y, Imajo K, Yoneda M, Nakahara T, Oeda S, Tanaka K, Amano Y, Ogawa S, Kawaguchi A, Aishima S, Kage M, Chayama K, Nakajima A, Eguchi Y. Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. JGH Open 2020;4:497-502. [PMID: 32514460 DOI: 10.1002/jgh3.12289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
203 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17. [PMID: 19065650 DOI: 10.1002/hep.22603] [Cited by in Crossref: 372] [Cited by in F6Publishing: 347] [Article Influence: 28.6] [Reference Citation Analysis]
204 Horoz M, Aslan M, Bolukbas FF, Bolukbas C, Nazligul Y, Celik H, Aksoy N. Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis. J Clin Lab Anal. 2010;24:207-211. [PMID: 20486204 DOI: 10.1002/jcla.20334] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
205 Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol. 2007;188:758-764. [PMID: 17312065 DOI: 10.2214/ajr.06.0322] [Cited by in Crossref: 222] [Cited by in F6Publishing: 76] [Article Influence: 14.8] [Reference Citation Analysis]
206 Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J. 2008;411:1-18. [PMID: 18333835 DOI: 10.1042/bj20071570] [Cited by in Crossref: 217] [Cited by in F6Publishing: 110] [Article Influence: 15.5] [Reference Citation Analysis]
207 Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011;5:625-634. [PMID: 21484142 DOI: 10.1007/s12072-010-9240-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
208 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
209 Wei Z, Ren Z, Hu S, Gao Y, Sun R, Lv S, Yang G, Yu Z, Kan Q. Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease. Cancer Med 2020;9:1254-62. [PMID: 31860170 DOI: 10.1002/cam4.2777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
210 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
211 Eddowes PJ, Mcdonald N, Davies N, Semple SIK, Kendall TJ, Hodson J, Newsome PN, Flintham RB, Wesolowski R, Blake L, Duarte RV, Kelly CJ, Herlihy AH, Kelly MD, Olliff SP, Hübscher SG, Fallowfield JA, Hirschfield GM. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2018;47:631-44. [DOI: 10.1111/apt.14469] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
212 Arslan FD, Karakoyun I, Tatar B, Pala EE, Yıldırım M, Ulasoglu C, Duman C, Akar H, Kose S, Isbilen Basok B. SHFI: A Novel Noninvasive Predictive Model for Significant Fibrosis in Patients With Chronic Hepatitis B. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.63310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011;18:23-31. [PMID: 20196799 DOI: 10.1111/j.1365-2893.2009.01263.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 109] [Article Influence: 9.8] [Reference Citation Analysis]
214 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 8.1] [Reference Citation Analysis]
215 Park G, Katelaris P, Jones DB, Ngu M, Le Couteur D. Caution before embracing serum markers of liver fibrosis in clinical practice. Gastroenterology 2005;128:1145-6. [DOI: 10.1053/j.gastro.2005.02.044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Lubner MG, Jones D, Kloke J, Said A, Pickhardt PJ. CT texture analysis of the liver for assessing hepatic fibrosis in patients with hepatitis C virus. Br J Radiol 2019;92:20180153. [PMID: 30182750 DOI: 10.1259/bjr.20180153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
217 Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M, Smid V, Haluzik M, Bruha R. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. PLoS One 2014;9:e111551. [PMID: 25350286 DOI: 10.1371/journal.pone.0111551] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
218 Ariz U, Mato JM, Lu SC, Martínez Chantar ML. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? Methods Mol Biol. 2010;593:109-136. [PMID: 19957147 DOI: 10.1007/978-1-60327-194-3_6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
219 Benlloch S, Heredia L, Barquero C, Rayón J, Pina R, Aguilera V, Prieto M, Berenguer M. Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients: Liver Transplantation HCV Fibrosis Index. Liver Transpl 2009;15:1798-807. [DOI: 10.1002/lt.21919] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
220 Bracht T, Mölleken C, Ahrens M, Poschmann G, Schlosser A, Eisenacher M, Stühler K, Meyer HE, Schmiegel WH, Holmskov U, Sorensen GL, Sitek B. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. J Transl Med 2016;14:201. [PMID: 27378383 DOI: 10.1186/s12967-016-0952-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
221 Sezai A, Hata M, Niino T, Kasamaki Y, Nakai T, Hirayama A, Minami K. Study of the factors related to atrial fibrillation after coronary artery bypass grafting: A search for a marker to predict the occurrence of atrial fibrillation before surgical intervention. The Journal of Thoracic and Cardiovascular Surgery 2009;137:895-900. [DOI: 10.1016/j.jtcvs.2008.10.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
222 Karsdal MA, Krarup H, Sand JM, Christensen PB, Gerstoft J, Leeming DJ, Weis N, Schaffalitzky de Muckadell OB, Krag A. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther. 2014;40:233-249. [PMID: 24909260 DOI: 10.1111/apt.12820] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
223 Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol 2018;33:291-7. [PMID: 28548299 DOI: 10.1111/jgh.13834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
224 Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012;36:824-32. [PMID: 22966946 DOI: 10.1111/apt.12044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
225 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
226 Dong XQ, Wu Z, Zhao H, Wang GQ; China HepB-Related Fibrosis Assessment Research Group. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat 2019;26:297-307. [PMID: 30380170 DOI: 10.1111/jvh.13031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
227 Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006; 12(23): 3682-3694 [PMID: 16773685 DOI: 10.3748/wjg.v12.i23.3682] [Cited by in CrossRef: 174] [Cited by in F6Publishing: 165] [Article Influence: 10.9] [Reference Citation Analysis]
228 Cadranel J, Castera L, Cales P. La ponction biopsie du foie dans le diagnostic et la prise en charge des maladies chroniques du foie. Gastroentérologie Clinique et Biologique 2006;30:121-3. [DOI: 10.1016/s0399-8320(06)73126-8] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
229 Park MS, Han K, Kim SU. Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease. Expert Review of Gastroenterology & Hepatology 2014;8:501-11. [DOI: 10.1586/17474124.2014.898563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
230 Kelly D, Verkade HJ, Rajanayagam J, Mckiernan P, Mazariegos G, Hübscher S. Late graft hepatitis and fibrosis in pediatric liver allograft recipients: Current concepts and future developments. Liver Transpl 2016;22:1593-602. [DOI: 10.1002/lt.24616] [Cited by in Crossref: 69] [Cited by in F6Publishing: 46] [Article Influence: 11.5] [Reference Citation Analysis]
231 He J, Wang P, Zhu J, Wu G, Ji J, Xue Y. Role of urinary biomarkers of N,N-dimethylformamide in the early detection of hepatic injury among occupational exposed workers. Int Arch Occup Environ Health 2010;83:399-406. [DOI: 10.1007/s00420-010-0520-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
232 Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley M, Yeoman A. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67:6-19. [PMID: 29122851 DOI: 10.1136/gutjnl-2017-314924] [Cited by in Crossref: 138] [Cited by in F6Publishing: 121] [Article Influence: 27.6] [Reference Citation Analysis]
233 Petersen JR, Stevenson HL, Kasturi KS, Naniwadekar A, Parkes J, Cross R, Rosenberg WM, Xiao SY, Snyder N. Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol. 2014;48:370-376. [PMID: 24045284 DOI: 10.1097/mcg.0b013e3182a87e78] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
234 Seen TK, Sayed M, Bilal M, Reyes JV, Bhandari P, Lourdusamy V, Al-khazraji A, Syed U, Sattar Y, Bansal R. Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis. World J Gastroenterol 2021; 27(23): 3238-3248 [PMID: 34163108 DOI: 10.3748/wjg.v27.i23.3238] [Reference Citation Analysis]
235 Peveler WJ, Yazdani M, Rotello VM. Selectivity and Specificity: Pros and Cons in Sensing. ACS Sens 2016;1:1282-5. [PMID: 30294676 DOI: 10.1021/acssensors.6b00564] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 13.0] [Reference Citation Analysis]
236 Stasi C, Tsochatzis EA, Hall A, Rosenberg W, Milani S, Dhillon AP, Pinzani M. Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. Dig Liver Dis 2019;51:1001-7. [PMID: 30606698 DOI: 10.1016/j.dld.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
237 Dioguardi N, Grizzi F, Fiamengo B, Russo C. Metrically measuring liver biopsy: A chronic hepatitis B and C computer-aided morphologic description. World J Gastroenterol 2008; 14(48): 7335-7344 [PMID: 19109867 DOI: 10.3748/wjg.14.7335] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
238 Cui Q, He F, Hu J, Li S, Guo D, Bie X, Liu W, Zhao Y. Evaluation of Rabbits Liver Fibrosis Using Gd-DTPA-BMA of Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Evid Based Complement Alternat Med 2021;2021:2791142. [PMID: 34567208 DOI: 10.1155/2021/2791142] [Reference Citation Analysis]
239 Dyvorne HA, Jajamovich GH, Bane O, Fiel MI, Chou H, Schiano TD, Dieterich D, Babb JS, Friedman SL, Taouli B. Prospective comparison of magnetic resonance imaging to transient elastography and serum markers for liver fibrosis detection. Liver Int. 2016;36:659-666. [PMID: 26744140 DOI: 10.1111/liv.13058] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
240 Jaafar RF, Hajj Ali AM, Zaghal AM, Kanso M, Habib SG, Halaoui AF, Daniel F, Mokaddem F, Khalife MJ, Mukherji DM, Faraj WG. Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2019;31:1540-4. [DOI: 10.1097/meg.0000000000001461] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
241 Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005;41:1376-82. [DOI: 10.1002/hep.20717] [Cited by in Crossref: 229] [Cited by in F6Publishing: 230] [Article Influence: 13.5] [Reference Citation Analysis]
242 Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373-1381. [PMID: 16317693 DOI: 10.1002/hep.20935] [Cited by in Crossref: 372] [Cited by in F6Publishing: 320] [Article Influence: 21.9] [Reference Citation Analysis]
243 Isman FK, Kucur M, Baysal B, Ozkan F. Evaluation of serum hyaluronic acid level and hyaluronidase activity in acute and chronic hepatitis C. J Int Med Res 2007;35:346-52. [PMID: 17593863 DOI: 10.1177/147323000703500309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
244 Ramezani-Moghadam M, Wang J, Ho V, Iseli TJ, Alzahrani B, Xu A, Van der Poorten D, Qiao L, George J, Hebbard L. Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion. J Biol Chem. 2015;290:5533-5542. [PMID: 25575598 DOI: 10.1074/jbc.m114.598011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
245 Pang JX, Zimmer S, Niu S, Crotty P, Tracey J, Pradhan F, Shaheen AA, Coffin CS, Heitman SJ, Kaplan GG, Swain MG, Myers RP. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One 2014;9:e95776. [PMID: 24755824 DOI: 10.1371/journal.pone.0095776] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 8.5] [Reference Citation Analysis]
246 Alboraie M, Khairy M, Elsharkawy A, Elsharkawy M, Asem N, Abo El-Seoud AR, Elghamry FG, Esmat G. Egy-score as a noninvasive score for the assessment of hepatic fibrosis in chronic hepatitis C: a preliminary approach. Saudi J Gastroenterol. 2014;20:170-174. [PMID: 24976280 DOI: 10.4103/1319-3767.133003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
247 Kelleher TB, Afdhal N. Assessment of liver fibrosis in co-infected patients. J Hepatol 2006;44:S126-31. [PMID: 16352364 DOI: 10.1016/j.jhep.2005.11.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
248 Lubner MG, Graffy PM, Said A, Watson R, Zea R, Malecki KM, Pickhardt PJ. Utility of Multiparametric CT for Identification of High-Risk NAFLD. AJR Am J Roentgenol 2021;216:659-68. [PMID: 33474981 DOI: 10.2214/AJR.20.22842] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
249 J.s. Cross T, Jothimani D, Heneghan MA, Harrison PM. Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence: Non-invasive assessment of HCV post OLT. Clinical Transplantation 2011;25:345-51. [DOI: 10.1111/j.1399-0012.2011.01396.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
250 Manco M, Bottazzo G, Devito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic Fatty Liver Disease in Children. Journal of the American College of Nutrition 2008;27:667-76. [DOI: 10.1080/07315724.2008.10719744] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
251 Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol. 2016;7:159. [PMID: 27378924 DOI: 10.3389/fphar.2016.00159] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
252 Lambrecht J, Verhulst S, Mannaerts I, Reynaert H, van Grunsven LA. Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard? Biochim Biophys Acta Mol Basis Dis. 2018;1864:1024-1036. [PMID: 29329986 DOI: 10.1016/j.bbadis.2018.01.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
253 Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, Manns MP, Schulze-osthoff K, Bantel H. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 2012;55:455-64. [DOI: 10.1002/hep.24734] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 11.4] [Reference Citation Analysis]
254 Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-49. [PMID: 17845148 DOI: 10.1517/14728222.11.9.1231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
255 Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol. 2008;32:52-57. [PMID: 18973846 DOI: 10.1016/s0399-8320(08)73993-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
256 Gawrieh S, Harlow KE, Pike F, Yates KP, Wilson LA, Cummings OW, Rosenberg WM, Chalasani N, Molleston JP. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. J Pediatr 2021:S0022-3476(21)00768-X. [PMID: 34400208 DOI: 10.1016/j.jpeds.2021.08.012] [Reference Citation Analysis]
257 Lebensztejn DM, Sobaniec-Łotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D. Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005;17:843-8. [PMID: 16003134 DOI: 10.1097/00042737-200508000-00011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
258 Patel K, Remlinger KS, Walker TG, Leitner P, Lucas JE, Gardner SD, Mchutchison JG, Irving W, Guha IN. Multiplex Protein Analysis to Determine Fibrosis Stage and Progression in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 2014;12:2113-2120.e3. [DOI: 10.1016/j.cgh.2014.04.037] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
259 Pagadala M, Zein CO, Mccullough AJ. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009;13:591-606. [DOI: 10.1016/j.cld.2009.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
260 Abdo AA, Al Swat K, Azzam N, Ahmed S, Al Faleh F. Validation of three noninvasive laboratory variables to predict significant fibrosis and cirrhosis in patients with chronic hepatitis C in Saudi Arabia. Ann Saudi Med 2007;27:89-93. [PMID: 17356320 DOI: 10.5144/0256-4947.2007.89] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
261 Larrousse M, Laguno M, Segarra M, De Lazzari E, Martinez E, Blanco JL, León A, Deulofeu R, Miquel R, Milinkovic A, Lonca M, Miró JM, Biglia A, Murillas J, Gatell JM, Mallolas J. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007;46:304-11. [PMID: 18172937 DOI: 10.1097/qai.0b013e3181520502] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
262 Fouad R, Elbaz T, Abdel Alem S, Elsharkawy A, Negm M, Khairy M, Hassany M, Cordie A, El Akel W, Esmat G. Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. Eur J Gastroenterol Hepatol 2018;30:882-7. [PMID: 29727382 DOI: 10.1097/MEG.0000000000001151] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
263 Shima T, Sakai K, Oya H, Katayama T, Mitsumoto Y, Mizuno M, Kanbara Y, Okanoue T. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2020;55:100-12. [PMID: 31538241 DOI: 10.1007/s00535-019-01626-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
264 Ratziu V, Martin L, Fedchuk L, Poynard T. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? Biomark Med 2009;3:353-61. [PMID: 20477484 DOI: 10.2217/bmm.09.36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
265 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
266 Puigvehí M, Hernández J, Broquetas T, Coll S, Garcia-Retortillo M, Cañete N, Giménez MD, Garcia M, Bory F, Salvadó M, Solà R, Carrión JA. Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years. PLoS One 2016;11:e0164883. [PMID: 27984583 DOI: 10.1371/journal.pone.0164883] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
267 Khalili H, Dayyeh BA, Friedman LS. Assessment of Liver Function in Clinical Practice. In: Ginès P, Kamath PS, Arroyo V, editors. Chronic Liver Failure. Totowa: Humana Press; 2011. pp. 47-76. [DOI: 10.1007/978-1-60761-866-9_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
268 Olveda DU, Inobaya M, Olveda RM, Vinluan ML, Ng SK, Weerakoon K, McManus DP, Ramm GA, Harn DA, Li Y, Lam AK, Guevarra JR, Ross AG. Diagnosing schistosomiasis-induced liver morbidity: implications for global control. Int J Infect Dis 2017;54:138-44. [PMID: 27816660 DOI: 10.1016/j.ijid.2016.10.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
269 Calès P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem. 2010;43:1315-1322. [PMID: 20713037 DOI: 10.1016/j.clinbiochem.2010.08.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
270 Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015; 21(41): 11567-11583 [PMID: 26556987 DOI: 10.3748/wjg.v21.i41.11567] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 105] [Article Influence: 17.1] [Reference Citation Analysis]
271 Tsukano N, Miyase S, Saeki T, Mizobe K, Iwashita H, Arima N, Fujiyama S. Usefulness of virtual touch quantification for staging liver fibrosis in patients with hepatitis C, and factors affecting liver stiffness measurement failure compared with liver biopsy: Usefulness of VTQ and factors of failure. Hepatol Res 2018;48:373-82. [DOI: 10.1111/hepr.13041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
272 Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34:1155-1161. [PMID: 24743428 DOI: 10.1161/atvbaha.114.303034] [Cited by in Crossref: 96] [Cited by in F6Publishing: 56] [Article Influence: 12.0] [Reference Citation Analysis]
273 Boursier J, Dib N, Oberti F, Calès P. Caractéristiques et interprétation des tests sanguins de fibrose hépatique. Gastroentérologie Clinique et Biologique 2007;31:511-23. [DOI: 10.1016/s0399-8320(07)89421-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
274 Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44:686-693. [PMID: 16490278 DOI: 10.1016/j.jhep.2006.01.007] [Cited by in Crossref: 193] [Cited by in F6Publishing: 171] [Article Influence: 12.1] [Reference Citation Analysis]
275 Alboraie MA, Afifi ME, Elghamry FG, Shalaby HA, Elshennawy GE, Abdelaziz AA, Shaheen MU, Abo El-Seoud AR. Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study. Hepat Mon 2013;13:e10810. [PMID: 24046790 DOI: 10.5812/hepatmon.10810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
276 Leroy V, Sturm N, Faure P, Trocme C, Marlu A, Hilleret MN, Morel F, Zarski JP. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61:28-34. [PMID: 24631902 DOI: 10.1016/j.jhep.2014.02.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
277 Alboraie M, Khairy M, Elsharkawy M, Asem N, Elsharkawy A, Esmat G. Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns' index in chronic hepatitis C virus. Hepatol Res. 2014; Jul 3. [Epub ahead of print]. [PMID: 24995544 DOI: 10.1111/hepr.12385] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
278 Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009;49:S96-S102. [PMID: 19399800 DOI: 10.1002/hep.22977] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
279 Guha I, Rosenberg W. Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and Other Modalities. Clinics in Liver Disease 2008;12:883-900. [DOI: 10.1016/j.cld.2008.07.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
280 Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines (Basel). 2019;6. [PMID: 30889791 DOI: 10.3390/medicines6010041] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 12.0] [Reference Citation Analysis]
281 Crespo G, Fernández-varo G, Mariño Z, Casals G, Miquel R, Martínez SM, Gilabert R, Forns X, Jiménez W, Navasa M. ARFI, FibroScan®, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. Journal of Hepatology 2012;57:281-7. [DOI: 10.1016/j.jhep.2012.03.016] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 10.9] [Reference Citation Analysis]
282 Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. Int J Hepatol. 2012;2012:231210. [PMID: 22530132 DOI: 10.1155/2012/231210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
283 van der Voort E, Wakkee M, Veldt-kok P, Darwish Murad S, Nijsten T. Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). Br J Dermatol 2017;176:1599-606. [DOI: 10.1111/bjd.15220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
284 Meurer SK, Karsdal MA, Weiskirchen R. Advances in the clinical use of collagen as biomarker of liver fibrosis. Expert Rev Mol Diagn 2020;20:947-69. [PMID: 32865433 DOI: 10.1080/14737159.2020.1814746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
285 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.5106] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
286 Irvine KM, Wockner LF, Hoffmann I, Horsfall LU, Fagan KJ, Bijin V, Lee B, Clouston AD, Lampe G, Connolly JE, Powell EE. Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers. PLoS One. 2016;11:e0167001. [PMID: 27861569 DOI: 10.1371/journal.pone.0167001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
287 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
288 Crawford DHG, Murphy TL, Ramm LE, Fletcher LM, Clouston AD, Anderson GJ, Subramaniam VN, Powell LW, Ramm GA. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009;49:418-25. [DOI: 10.1002/hep.22650] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
289 Castera L. Quels outils pour le diagnostic non invasif de la stéatose et de la fibrose chez les patients atteints de stéatopathie métabolique ? Gastroentérologie Clinique et Biologique 2009;33:405-12. [DOI: 10.1016/j.gcb.2009.02.030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
290 Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-rust M, Sarrazin C, Zeuzem S, Welker M. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 2016;23:994-1002. [DOI: 10.1111/jvh.12578] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 15.3] [Reference Citation Analysis]
291 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
292 Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:16. [PMID: 30115921 DOI: 10.1038/s41572-018-0014-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 195] [Article Influence: 47.8] [Reference Citation Analysis]
293 Li T, Yu G, Guo T, Qi H, Bing Y, Xiao Y, Li C, Liu W, Yuan Y, He Y, Liu Z, Liu Q. The plasma S-adenosylmethionine level is associated with the severity of hepatitis B-related liver disease. Medicine (Baltimore) 2015;94:e489. [PMID: 25634198 DOI: 10.1097/MD.0000000000000489] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
294 Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50:165-173. [PMID: 18977552 DOI: 10.1016/j.jhep.2008.07.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 12.1] [Reference Citation Analysis]
295 Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Annals of Hepatology 2009;8:S25-33. [DOI: 10.1016/s1665-2681(19)31823-x] [Cited by in Crossref: 27] [Article Influence: 2.1] [Reference Citation Analysis]
296 Gawrieh S, Wilson LA, Cummings OW, Clark JM, Loomba R, Hameed B, Abdelmalek MF, Dasarathy S, Neuschwander-Tetri BA, Kowdley K, Kleiner D, Doo E, Tonascia J, Sanyal A, Chalasani N; NASH Clinical Research Network. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. Am J Gastroenterol 2019;114:1626-35. [PMID: 31517638 DOI: 10.14309/ajg.0000000000000388] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
297 Sharma C, Cococcia S, Ellis N, Parkes J, Rosenberg W. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. J Gastroenterol Hepatol 2021;36:1788-802. [PMID: 33668077 DOI: 10.1111/jgh.15482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
298 Xun YH, Zang GQ, Guo JC, Yu XL, Liu H, Xiang J, Liu J, Shi JP. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol. 2013;28:1746-1755. [PMID: 23800140 DOI: 10.1111/jgh.12304] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
299 Bang CS, Kang HY, Choi GH, Kim SB, Lee W, Song IH. The Performance of Serum Biomarkers for Predicting Fibrosis in Patients with Chronic Viral Hepatitis. Korean J Gastroenterol 2017;69:298-307. [PMID: 28539035 DOI: 10.4166/kjg.2017.69.5.298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
300 Paradis V. Glycomics: A new taste of cirrhosis marker. Journal of Hepatology 2005;43:913-4. [DOI: 10.1016/j.jhep.2005.08.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
301 Sporea I, Şirli R, Deleanu A, Tudora A, Popescu A, Curescu M, Bota S. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: A comparative study. World J Gastroenterol 2010; 16(38): 4832-4837 [PMID: 20939112 DOI: 10.3748/wjg.v16.i38.4832] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
302 Carneiro de Moura M, Marinho R. [Natural history and clinical manifestations of chronic hepatitis B virus]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:11-8. [PMID: 19100227 DOI: 10.1016/s0213-005x(08)76515-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
303 Yarnykh VL, Tartaglione EV, Ioannou GN. Fast macromolecular proton fraction mapping of the human liver in vivo for quantitative assessment of hepatic fibrosis. NMR Biomed 2015;28:1716-25. [PMID: 26503401 DOI: 10.1002/nbm.3437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
304 Shin WG, Park SH, Jun SY, Jung JO, Moon JH, Kim JP, Kim KO, Park CH, Hahn TH, Yoo KS, Kim JH, Park CK. Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases. Gut Liver 2007;1:145-50. [PMID: 20485631 DOI: 10.5009/gnl.2007.1.2.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
305 Martyn-simmons C, Rosenberg W, Cross R, Wong T, Smith C, Barker J. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study. Br J Dermatol 2014;171:267-73. [DOI: 10.1111/bjd.12782] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
306 Zhang X, Huang P, Wang X, Zhou K, Chen F, Zhou C, Yu L, Lu Q, Zhou J, Hu J, Wang Z. Development and validation of a non-invasive model for diagnosing HBV-related liver cirrhosis. Clin Chim Acta 2021;523:525-31. [PMID: 34748781 DOI: 10.1016/j.cca.2021.11.004] [Reference Citation Analysis]
307 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 64-85. [DOI: 10.1016/b978-1-4377-0881-3.00005-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
308 Cross TJ, Calvaruso V, Maimone S, Carey I, Chang TP, Pleguezuelo M, Manousou P, Quaglia A, Grillo F, Dhillon AP. Prospective comparison of Fibroscan, King’s score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat. 2010;17:546-554. [PMID: 19874477 DOI: 10.1111/j.1365-2893.2009.01210.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
309 Gunes Yegin E, Durusoy SS, Ture Ozdemir F, Kombak EF, Ataizi-Celikel C, Ozdogan OC. Appraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis. Ann Hepatol 2019;18:833-40. [PMID: 31558418 DOI: 10.1016/j.aohep.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M;  APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325. [PMID: 16729309 DOI: 10.1002/hep.21178] [Cited by in Crossref: 1954] [Cited by in F6Publishing: 1862] [Article Influence: 122.1] [Reference Citation Analysis]
311 Nguyen-khac E. Résultats et place du Fibroscan® dans le diagnostic non invasif de la fibrose hépatique. La Revue de Médecine Interne 2007;28:94-102. [DOI: 10.1016/j.revmed.2006.10.329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
312 Lebensztejn DM, Skiba E, Tobolczyk J, Sobaniec-Lotowska ME, Kaczmarski M. Diagnostic accuracy of serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics analysis. World J Gastroenterol 2005;11:7192-6. [PMID: 16437671 DOI: 10.3748/wjg.v11.i45.7192] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
313 Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582-589. [PMID: 17661414 DOI: 10.1002/hep.21768] [Cited by in Crossref: 294] [Cited by in F6Publishing: 282] [Article Influence: 19.6] [Reference Citation Analysis]
314 Maggio R, Viscomi C, Andreozzi P, D'Ettorre G, Viscogliosi G, Barbaro B, Gori M, Vullo V, Balsano C. Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection. PLoS One 2014;9:e112346. [PMID: 25532016 DOI: 10.1371/journal.pone.0112346] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
315 Zhang YX, Wu WJ, Zhang YZ, Feng YL, Zhou XX, Pan Q. Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(46): 7117-7121 [PMID: 19084920 DOI: 10.3748/wjg.14.7117] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
316 Macpherson I, Nobes JH, Dow E, Furrie E, Miller MH, Robinson EM, Dillon JF. Intelligent Liver Function Testing: Working Smarter to Improve Patient Outcomes in Liver Disease. The Journal of Applied Laboratory Medicine 2020;5:1090-100. [DOI: 10.1093/jalm/jfaa109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Wasmuth HE, Trautwein C. Prediction of fibrosis progression in hepatitis C infection: Are genetics ready for clinical use? Journal of Hepatology 2011;55:3-4. [DOI: 10.1016/j.jhep.2011.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
318 Halfon P, Bourlière M, Pénaranda G, Cacoub P. [Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]. Rev Med Interne 2006;27:751-61. [PMID: 16815598 DOI: 10.1016/j.revmed.2006.03.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
319 Guéchot J. Non-invasive evaluation of liver fibrosis: More well-validated tests available for patient management. Liver Int 2015;35:1643-5. [DOI: 10.1111/liv.12790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
320 Testa E, Malfatti F, Milazzo S, Cordiviola C, Cotellessa T, Marabotto E, Giannini E, Ceppa P, Mamone M, Risso D. Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease. Liver Int. 2006;26:439-444. [PMID: 16629647 DOI: 10.1111/j.1478-3231.2006.01251.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
321 Smirne C, Rigamonti C, De Benedittis C, Sainaghi PP, Bellan M, Burlone ME, Castello LM, Avanzi GC. Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis. Dis Markers 2019;2019:2304931. [PMID: 31583026 DOI: 10.1155/2019/2304931] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
322 Guéchot J. [Noninvasive assessment of liver fibrosis in patients with chronic hepatitis virus C]. Presse Med. 2006;35:1317-1326. [PMID: 16969327 DOI: 10.1016/s0755-4982(06)74811-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
323 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
324 Dioguardi N, Grizzi F, Franceschini B, Bossi P, Russo C. Liver fibrosis and tissue architectural change measurement using fractal-rectified metrics and Hurst’s exponent. World J Gastroenterol 2006; 12(14): 2187-2194 [PMID: 16610019 DOI: 10.3748/wjg.v12.i14.2187] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
325 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. [PMID: 24252302 DOI: 10.1186/2050-7771-1-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
326 Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105-117. [PMID: 22872786 DOI: 10.4137/bmi.s10009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
327 Thuluvath PJ, Krok KL. Noninvasive Markers of Fibrosis for Longitudinal Assessment of Fibrosis in Chronic Liver Disease: Are They Ready for Prime Time? Am J Gastroenterol 2006;101:1497-9. [DOI: 10.1111/j.1572-0241.2005.00304.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
328 Camacho VR, Silveira TR, Oliveira JR, Barros SG, Cerski CT. Relationship between serum concetrations of type III procollagen, hyluronic acid and histopathological findings in the liver of HCV-positive blood donors. Arq Gastroenterol 2007;44:118-22. [PMID: 17962855 DOI: 10.1590/s0004-28032007000200006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
329 Kuhn J, Gressner OA, Götting C, Gressner AM, Kleesiek K. Increased serum xylosyltransferase activity in patients with liver fibrosis. Clinica Chimica Acta 2009;409:123-6. [DOI: 10.1016/j.cca.2009.09.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
330 Denzer UW, Lüth S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 2009;23:453-60. [PMID: 19505671 DOI: 10.1016/j.bpg.2009.03.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
331 Huang Q, Wei L, Liang C, Nie J, Lu S, Lu C, Tan S, Lv S, Zhuo L, Lu Z, Lin X. Loss of Raf kinase inhibitor protein is associated with malignant progression in hepatic fibrosis. Biomed Pharmacother 2016;82:669-76. [PMID: 27470410 DOI: 10.1016/j.biopha.2016.06.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
332 Muddu AK, Guha IN, Elsharkawy AM, Mann DA. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol 2007;39:695-714. [PMID: 17110155 DOI: 10.1016/j.biocel.2006.10.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
333 Abdel Alem S, Elsharkawy A, El Akel W, Abdelaziz AO, Salama RM, El-Sayed MH, El Kassas M, Anees M, Shedeed M, Abdelsalam F, Ziada DH, El Shazly Y, El-Serafy M, Waked I, Esmat G, Doss W. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Rev Gastroenterol Hepatol 2019;13:1009-16. [PMID: 31418303 DOI: 10.1080/17474124.2019.1653183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
334 Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol. 2005;43:1045-1054. [PMID: 16223543 DOI: 10.1016/j.jhep.2005.06.025] [Cited by in Crossref: 171] [Cited by in F6Publishing: 164] [Article Influence: 10.1] [Reference Citation Analysis]
335 Martinez SM, Fernández-Varo G, González P, Sampson E, Bruguera M, Navasa M, Jiménez W, Sánchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:138-148. [PMID: 21083589 DOI: 10.1111/j.1365-2036.2010.04500.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.4] [Reference Citation Analysis]
336 Liu C, Sun Y, Yang Y, Feng Y, Xie X, Qi L, Liu K, Wang X, Zhu Q, Zhao X. Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis. Eur Radiol 2021;31:5840-50. [PMID: 33533990 DOI: 10.1007/s00330-021-07702-6] [Reference Citation Analysis]
337 Czaja AJ. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:385-406. [PMID: 24387318 DOI: 10.1111/apt.12592] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
338 Lykiardopoulos B, Hagström H, Fredrikson M, Ignatova S, Stål P, Hultcrantz R, Ekstedt M, Kechagias S. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One 2016;11:e0167776. [PMID: 27936091 DOI: 10.1371/journal.pone.0167776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
339 Guha IN, Bokhandi S, Ahmad Z, Sheron N, Cope R, Marshall C, Veldtman G. Structural and functional uncoupling of liver performance in the Fontan circulation. International Journal of Cardiology 2013;164:77-81. [DOI: 10.1016/j.ijcard.2011.06.062] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
340 Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, Oberti F, Fouchard-Hubert I, Dib N. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 2009;29:1507-1515. [PMID: 19725892 DOI: 10.1111/j.1478-3231.2009.02101.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 6.7] [Reference Citation Analysis]
341 Kim BK, Kim H, Yoo EJ, Oh EJ, Park JY, Kim DY, Ahn SH, Han K, Kim SU, Park YN. Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 2014;60:1911-9. [DOI: 10.1002/hep.27389] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
342 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Ladero JM, Delkader J, Ortega L, Fernández C, Devesa MJ, López-alonso G, Mayol J, Cuenca F, Suárez A, Taxonera C, Díaz-rubio M. Non-invasive evaluation of the fibrosis stage in chronic hepatitis C: A comparative analysis of nine scoring methods. Scandinavian Journal of Gastroenterology 2009;45:51-9. [DOI: 10.3109/00365520903305544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
344 Ahmed MH, Byrne CD. Non-Alcoholic Fatty Liver Disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndrome. Oxford: Wiley-Blackwell; 2011. pp. 245-77. [DOI: 10.1002/9781444347319.ch15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
345 Baranova A, Younossi ZM. The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology. 2008;47:373-375. [PMID: 18220279 DOI: 10.1002/hep.22140] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
346 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
347 Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep 2021;3:100219. [PMID: 33659890 DOI: 10.1016/j.jhepr.2020.100219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
348 Abbattista T, Ridolfi F, Consalvo GT, Brunelli E. Hepatic Vein Arrival Time for Diagnosis of Liver Cirrhosis: A 10-Year Single-Center Experience With Contrast-Enhanced Sonography. J Ultrasound Med 2016;35:2121-8. [PMID: 27503751 DOI: 10.7863/ultra.15.09026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
349 Sandahl TD, Mcgrail R, Møller HJ, Reverter E, Møller S, Turon F, Hernández-gea V, Bendtsen F, Vilstrup H, Garcia-pagan JC, Grønbaek H. The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. Aliment Pharmacol Ther 2016;43:1222-31. [DOI: 10.1111/apt.13618] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
350 Shiha G. Serum hyaluronic acid: a promising marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol 2008;14:161-2. [PMID: 19568531 DOI: 10.4103/1319-3767.43272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
351 King A, Barton D, Beard HA, Than N, Moore J, Corbett C, Thomas J, Guo K, Guha I, Hollyman D, Stocken D, Yap C, Fox R, Forbes SJ, Newsome PN. REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. BMJ Open 2015;5:e007700. [PMID: 25795699 DOI: 10.1136/bmjopen-2015-007700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
352 Kang W, Kim SU, Ahn SH. Non-invasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol 2014; 20(10): 2613-2623 [PMID: 24627597 DOI: 10.3748/wjg.v20.i10.2613] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
353 Hayee BH, Harris AW. Methotrexate for Crohn's disease: experience in a district general hospital. Eur J Gastroenterol Hepatol 2005;17:893-8. [PMID: 16093864 DOI: 10.1097/00042737-200509000-00002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
354 de Franchis R, Dell’Era A. Non-invasive diagnosis of cirrhosis and the natural history of its complications. Best Pract Res Clin Gastroenterol. 2007;21:3-18. [PMID: 17223493 DOI: 10.1016/j.bpg.2006.07.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
355 Park SH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy? Clinical Biochemistry 2010;43:877-81. [DOI: 10.1016/j.clinbiochem.2010.04.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
356 Day JW, Rosenberg WM. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. Br J Hosp Med 2018;79:694-9. [DOI: 10.12968/hmed.2018.79.12.694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
357 Ichino N, Osakabe K, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Arima Y, Shimazaki H, Suzuki K, Yoshioka K. A new index for non-invasive assessment of liver fibrosis. World J Gastroenterol 2010; 16(38): 4809-4816 [PMID: 20939109 DOI: 10.3748/wjg.v16.i38.4809] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
358 Zvibel I, Halfon P, Fishman S, Penaranda G, Leshno M, Or AB, Halpern Z, Oren R. Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C. Liver Int 2009;29:208-12. [PMID: 18694404 DOI: 10.1111/j.1478-3231.2008.01830.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
359 Nishikawa H, Takata R, Enomoto H, Yoh K, Kishino K, Shimono Y, Iwata Y, Hasegawa K, Nakano C, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Ishii A, Iijima H, Nishiguchi S. Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C: Predictive model, liver fibrosis and WFA + -M2BP. Hepatol Res 2017;47:E74-84. [DOI: 10.1111/hepr.12724] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
360 Khoo EYH, Stevenson MC, Leverton E, Cross R, Eriksson JW, Poucher SM, Spendlove I, Morris PG, Macdonald IA, Mansell P, Aithal GP. Elevation of Alanine Transaminase and Markers of Liver Fibrosis After a Mixed Meal Challenge in Individuals with Type 2 Diabetes. Dig Dis Sci 2012;57:3017-25. [DOI: 10.1007/s10620-012-2219-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
361 Tutar O, Beşer ÖF, Adaletli I, Tunc N, Gulcu D, Kantarci F, Mihmanli I, Cokugras FC, Kutlu T, Ozbay G, Erkan T. Shear wave elastography in the evaluation of liver fibrosis in children. J Pediatr Gastroenterol Nutr 2014;58:750-5. [PMID: 24552673 DOI: 10.1097/MPG.0000000000000329] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
362 Gangadharan B, Bapat M, Rossa J, Antrobus R, Chittenden D, Kampa B, Barnes E, Klenerman P, Dwek RA, Zitzmann N. Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study. PLoS One 2012;7:e39603. [PMID: 22761838 DOI: 10.1371/journal.pone.0039603] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
363 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
364 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 127] [Article Influence: 13.2] [Reference Citation Analysis]
365 Omran D, Yosry A, Darweesh SK, Nabeel MM, El-Beshlawey M, Saif S, Fared A, Hassany M, Zayed RA. Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients. Clin Exp Med 2018;18:45-50. [PMID: 28567544 DOI: 10.1007/s10238-017-0463-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
366 Zhao Y, Shi X, Ding C, Feng D, Li Y, Hu Y, Wang L, Gao D, Tian X, Yao J. Carnosic acid prevents COL1A2 transcription through the reduction of Smad3 acetylation via the AMPKα1/SIRT1 pathway. Toxicol Appl Pharmacol 2018;339:172-80. [PMID: 29253500 DOI: 10.1016/j.taap.2017.12.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
367 Tanwar S, Srivastava A, Rosenberg W. Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease. J Hepatol 2020;73:1580-1. [PMID: 32994080 DOI: 10.1016/j.jhep.2020.07.009] [Reference Citation Analysis]
368 Lambrecht J, Verhulst S, Mannaerts I, Sowa JP, Best J, Canbay A, Reynaert H, van Grunsven LA. A PDGFRβ-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. EBioMedicine 2019;43:501-12. [PMID: 31036530 DOI: 10.1016/j.ebiom.2019.04.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
369 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 787] [Article Influence: 131.1] [Reference Citation Analysis]
370 Ippolito DL, Abdulhameed MDM, Tawa GJ, Baer CE, Permenter MG, Mcdyre BC, Dennis WE, Boyle MH, Hobbs CA, Streicker MA, Snowden BS, Lewis JA, Wallqvist A, Stallings JD. Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis. Toxicol Sci 2016;149:67-88. [DOI: 10.1093/toxsci/kfv214] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
371 Hung HH, Su CW, Lai CR, Chau GY, Chan CC, Huang YH, Huo TI, Lee PC, Kao WY, Lee SD. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma. Hepatol Int. 2010;4:691-699. [PMID: 21286339 DOI: 10.1007/s12072-010-9213-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
372 Voumvouraki A, Koulentaki M, Notas G, Sfakianaki O, Kouroumalis E. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med. 2011;22:77-83. [PMID: 21238899 DOI: 10.1016/j.ejim.2010.10.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
373 Douglass A, Wallace K, Koruth M, Barelle C, Porter AJ, Wright MC. Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatol Int 2008;2:405-15. [PMID: 19669316 DOI: 10.1007/s12072-008-9093-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
374 Lee MH, Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Yang JM, Han KH, Cho SW. Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. Dig Dis Sci. 2010;55:3552-3560. [PMID: 20428950 DOI: 10.1007/s10620-010-1219-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
375 Thomas JA, Aithal GP. Monitoring Liver Function during Methotrexate Therapy for Psoriasis: Are Routine Biopsies Really Necessary? American Journal of Clinical Dermatology 2005;6:357-63. [DOI: 10.2165/00128071-200506060-00003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
376 Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-921. [PMID: 17705266 DOI: 10.1002/hep.21835] [Cited by in Crossref: 251] [Cited by in F6Publishing: 239] [Article Influence: 16.7] [Reference Citation Analysis]
377 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 15.0] [Reference Citation Analysis]
378 Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Intern Med 2005;258:460-6. [PMID: 16238682 DOI: 10.1111/j.1365-2796.2005.01564.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
379 Giuffrida P, Pinzani M, Corazza GR, Di Sabatino A. Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease. United European Gastroenterol J 2016;4:523-30. [PMID: 27536362 DOI: 10.1177/2050640616640160] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
380 Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, Soloway R, Petersen J. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40:535-542. [PMID: 16825937 DOI: 10.1097/00004836-200607000-00013] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
381 Said M. Evaluation of routine biochemical indices and α-fetoprotein versus histology in chronic hepatitis C patients. Arab Journal of Gastroenterology 2009;10:87-91. [DOI: 10.1016/j.ajg.2009.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
382 Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014;21:430-8. [PMID: 24750297 DOI: 10.1111/jvh.12161] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
383 Peveler WJ, Landis RF, Yazdani M, Day JW, Modi R, Carmalt CJ, Rosenberg WM, Rotello VM. A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array. Adv Mater 2018;30:e1800634. [PMID: 29797373 DOI: 10.1002/adma.201800634] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
384 Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 2014;5:21. [PMID: 25937854 DOI: 10.1186/1878-5085-5-21] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
385 Ouchi R, Togo S, Kimura M, Shinozawa T, Koido M, Koike H, Thompson W, Karns RA, Mayhew CN, McGrath PS, McCauley HA, Zhang RR, Lewis K, Hakozaki S, Ferguson A, Saiki N, Yoneyama Y, Takeuchi I, Mabuchi Y, Akazawa C, Yoshikawa HY, Wells JM, Takebe T. Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids. Cell Metab. 2019;30:374-384.e6. [PMID: 31155493 DOI: 10.1016/j.cmet.2019.05.007] [Cited by in Crossref: 111] [Cited by in F6Publishing: 107] [Article Influence: 37.0] [Reference Citation Analysis]
386 Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells 2020;9:E1005. [PMID: 32316690 DOI: 10.3390/cells9041005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
387 Zhu X, Wang L, Chen E, Chen X, Chen L, Liu L, Lei X, Liu C, Tang H. Prospective Evaluation of FibroScan for the Diagnosis of Hepatic Fibrosis Compared with Liver Biopsy/AST Platelet Ratio Index and FIB-4 in Patients with Chronic HBV Infection. Dig Dis Sci 2011;56:2742-9. [DOI: 10.1007/s10620-011-1659-1] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
388 Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455-460. [PMID: 18038452 DOI: 10.1002/hep.21984] [Cited by in Crossref: 450] [Cited by in F6Publishing: 405] [Article Influence: 32.1] [Reference Citation Analysis]
389 Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem. 2016;49:302-315. [PMID: 26188920 DOI: 10.1016/j.clinbiochem.2015.07.019] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
390 Floreani A, Cazzagon N, Martines D, Cavalletto L, Baldo V, Chemello L. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Digestive and Liver Disease 2011. [DOI: 10.1016/j.dld.2011.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
391 Mendes LC, Stucchi RS, Vigani AG. Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies. Hepat Med. 2018;10:13-22. [PMID: 29662329 DOI: 10.2147/hmer.s125234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
392 Miyasato M, Murase-mishiba Y, Bessho M, Miyawaki M, Imbe H, Tsutsumi C, Tanimoto K, Imagawa A, Terasaki J, Hanafusa T. The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Clinica Chimica Acta 2014;433:184-9. [DOI: 10.1016/j.cca.2014.03.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
393 Fagan KJ, Pretorius CJ, Horsfall LU, Irvine KM, Wilgen U, Choi K, Fletcher LM, Tate J, Melino M, Nusrat S, Miller GC, Clouston AD, Ballard E, O'Rourke P, Lampe G, Ungerer JP, Powell EE. ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity. Liver Int 2015;35:1673-81. [PMID: 25495373 DOI: 10.1111/liv.12760] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
394 Berenguer J, Bellón JM, Miralles P, Alvarez E, Sánchez-Conde M, Cosín J, López JC, Alvarez F, Catalán P, Resino S. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007;14:859-69. [PMID: 18070289 DOI: 10.1111/j.1365-2893.2007.00881.x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
395 Paggi S, Colli A, Fraquelli M, Viganò M, Poggio PD, Facciotto C, Colombo M, Ronchi G, Conte D. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: A comparison using histology with internal–external validation. Journal of Hepatology 2008;49:564-71. [DOI: 10.1016/j.jhep.2008.07.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
396 Brady CW, Mchutchison JG, Patel K. Fibrosis markers in hepatitis C. Curr hepatitis rep 2006;5:86-93. [DOI: 10.1007/s11901-006-0010-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
397 Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM. Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. Gastroenterology 2009;136:160-7. [DOI: 10.1053/j.gastro.2008.09.013] [Cited by in Crossref: 173] [Cited by in F6Publishing: 163] [Article Influence: 13.3] [Reference Citation Analysis]
398 Parola M. Age-dependent changes in extracellular matrix turnover: An under evaluated issue in the approach to chronic liver diseases. J Hepatol 2016;64:13-5. [PMID: 26432685 DOI: 10.1016/j.jhep.2015.09.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
399 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s9051] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
400 Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019;48:281-289. [PMID: 31046975 DOI: 10.1016/j.gtc.2019.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
401 Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy. European Journal of Gastroenterology & Hepatology 2017;29:289-96. [DOI: 10.1097/meg.0000000000000789] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
402 Kogachi S, Noureddin M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Ther 2021;43:455-72. [PMID: 33581876 DOI: 10.1016/j.clinthera.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
403 Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-1698. [PMID: 18471547 DOI: 10.1053/j.gastro.2008.02.077] [Cited by in Crossref: 233] [Cited by in F6Publishing: 228] [Article Influence: 16.6] [Reference Citation Analysis]
404 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
405 Zhou K, Gao CF, Zhao YP, Liu HL, Zheng RD, Xian JC, Xu HT, Mao YM, Zeng MD, Lu LG. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25:1569-1577. [PMID: 20796157 DOI: 10.1111/j.1440-1746.2010.06383.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 5.9] [Reference Citation Analysis]
406 Jin HH, Li ZP. Correlation between serum hyaluronic acid and HBV DNA levels in patients with hepatitis B-associated cirrhosis. Shijie Huaren Xiaohua Zazhi 2012; 20(3): 229-232 [DOI: 10.11569/wcjd.v20.i3.229] [Reference Citation Analysis]
407 French AL, Hotton A, Young M, Nowicki M, Augenbraun M, Anastos K, Seaberg E, Rosenberg W, Peters MG. Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. J Acquir Immune Defic Syndr 2016;72:274-80. [PMID: 26918547 DOI: 10.1097/QAI.0000000000000969] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
408 Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. Am J Gastroenterology 2007;102:2589-600. [DOI: 10.1111/j.1572-0241.2007.01466.x] [Cited by in Crossref: 233] [Cited by in F6Publishing: 219] [Article Influence: 15.5] [Reference Citation Analysis]
409 Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh RC, Cotton D. Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection. American Journal of Gastroenterology 2010;105:1346-53. [DOI: 10.1038/ajg.2009.746] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 9.3] [Reference Citation Analysis]
410 Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017;51:268-77. [PMID: 27380461 DOI: 10.1097/MCG.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
411 Attallah AM, Mosa TE, Omran MM, Abo-Zeid MM, El-Dosoky I, Shaker YM. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV. J Immunoassay Immunochem 2007;28:155-68. [PMID: 17424834 DOI: 10.1080/15321810701212088] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
412 Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW, Yu H, Kim M, Kim Y, Sung PS, Yoon SK. Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients. Ann Lab Med. 2018;38:348-354. [PMID: 29611385 DOI: 10.3343/alm.2018.38.4.348] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
413 Shackel NA, Seth D, Haber PS, Gorrell MD, McCaughan GW. The hepatic transcriptome in human liver disease. Comp Hepatol 2006;5:6. [PMID: 17090326 DOI: 10.1186/1476-5926-5-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
414 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25:291-303. [PMID: 21497746 DOI: 10.1016/j.bpg.2011.02.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 8.3] [Reference Citation Analysis]
415 Carrión JA, Navasa M, Buti M, Torras X, Xiol X, Vergara M, Planas R, Solà R, Forns X. Elastografía hepática. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2011;34:504-10. [DOI: 10.1016/j.gastrohep.2011.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
416 Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med. 2011;3:69-80. [PMID: 24367223 DOI: 10.2147/hmer.s905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
417 Miller MH, Walsh SV, Atrih A, Huang JT, Ferguson MA, Dillon JF. Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2014;29:1839-47. [PMID: 24750217 DOI: 10.1111/jgh.12614] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
418 Gheorghe G, Bungău S, Ceobanu G, Ilie M, Bacalbaşa N, Bratu OG, Vesa CM, Găman MA, Diaconu CC. The non-invasive assessment of hepatic fibrosis. J Formos Med Assoc 2021;120:794-803. [PMID: 32861550 DOI: 10.1016/j.jfma.2020.08.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
419 Inadomi C, Takahashi H, Ogawa Y, Oeda S, Imajo K, Kubotsu Y, Tanaka K, Kessoku T, Okada M, Isoda H, Akiyama T, Fukushima H, Yoneda M, Anzai K, Aishima S, Nakajima A, Eguchi Y. Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non‐invasive tests for the diagnosis of advanced liver fibrosis in patients with non‐alcoholic fatty liver disease. Hepatol Res 2020;50:682-92. [DOI: 10.1111/hepr.13495] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
420 Angulo P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroentérologie Clinique et Biologique 2009;33:940-8. [DOI: 10.1016/j.gcb.2009.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
421 Baršić N, Lerotić I, Smirčić-Duvnjak L, Tomašić V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(30): 3945-3954 [PMID: 22912545 DOI: 10.3748/wjg.v18.i30.3945] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
422 Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology 2018;68:349-60. [PMID: 29222917 DOI: 10.1002/hep.29721] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
423 de Carli MA, de Carli LA, Correa MB, Junqueira G, Tovo CV, Coral GP. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2020;32:420-5. [DOI: 10.1097/meg.0000000000001519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
424 Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2:563-575. [PMID: 17699464 DOI: 10.2215/cjn.02930806] [Cited by in Crossref: 56] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
425 Attia D, Pischke S, Negm AA, Rifai K, Manns MP, Gebel MJ, Lankisch TO, Potthoff A. Changes in liver stiffness using acoustic radiation force impulse imaging in patients with obstructive cholestasis and cholangitis. Dig Liver Dis. 2014;46:625-631. [PMID: 24666759 DOI: 10.1016/j.dld.2014.02.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
426 Ragazzo TG, Paranagua-Vezozzo D, Lima FR, de Campos Mazo DF, Pessoa MG, Oliveira CP, Alves VAF, Carrilho FJ. Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C. Clinics (Sao Paulo) 2017;72:516-25. [PMID: 29069254 DOI: 10.6061/clinics/2017(09)01] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
427 Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer H, Heidrich B. Non-invasive fibrosis score for hepatitis delta. Liver Int. 2017;37:196-204. [PMID: 27428078 DOI: 10.1111/liv.13205] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
428 Cheung RC, Currie S, Shen H, Bini EJ, Ho SB, Anand BS, Hu KQ, Wright TL, Morgan TR;  VA HCV-001 Study Group. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol. 2008;42:827-834. [PMID: 18285716 DOI: 10.1097/mcg.0b013e318046ea9a] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
429 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 368] [Article Influence: 41.1] [Reference Citation Analysis]
430 Kawaguchi T, Ide T, Amano K, Arinaga-Hino T, Kuwahara R, Sano T, Miki S, Ono N, Torimura T. Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. Mol Clin Oncol 2021;15:215. [PMID: 34476099 DOI: 10.3892/mco.2021.2377] [Reference Citation Analysis]
431 Irvine KM, Wockner LF, Shanker M, Fagan KJ, Horsfall LU, Fletcher LM, Ungerer JP, Pretorius CJ, Miller GC, Clouston AD, Lampe G, Powell EE. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease. Liver Int 2016;36:370-7. [PMID: 26104018 DOI: 10.1111/liv.12896] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
432 Mueller S, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20(40): 14626-14641 [PMID: 25356026 DOI: 10.3748/wjg.v20.i40.14626] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 52] [Article Influence: 9.1] [Reference Citation Analysis]
433 Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224-1229, 1229.e1-1229. e2. [PMID: 19559819 DOI: 10.1016/j.cgh.2009.06.007] [Cited by in Crossref: 170] [Cited by in F6Publishing: 160] [Article Influence: 13.1] [Reference Citation Analysis]
434 Albanis E, Friedman SL. Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. Clin Liver Dis. 2006;10:821-833. [PMID: 17164119 DOI: 10.1016/j.cld.2006.08.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
435 Liu CH, Hsu SJ, Lin JW, Hwang JJ, Liu CJ, Yang PM, Lai MY, Chen PJ, Chen JH, Kao JH. Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Clin Gastroenterol Hepatol. 2007;5:1199-1206.e1. [PMID: 17916547 DOI: 10.1016/j.cgh.2007.07.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
436 Wahl K, Rosenberg W, Vaske B, Manns MP, Schulze-Osthoff K, Bahr MJ, Bantel H. Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS One 2012;7:e51906. [PMID: 23284811 DOI: 10.1371/journal.pone.0051906] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
437 Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carrilho FJ, Largura A, Arrese M, Oliveira CP. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol 2021;20:100253. [PMID: 32949785 DOI: 10.1016/j.aohep.2020.08.070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
438 Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Crit Rev Clin Lab Sci. 2016;53:106-120. [PMID: 26463349 DOI: 10.3109/10408363.2015.1092106] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
439 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
440 Gokce O, Ozenirler S, Atak Yucel A, Oruklu N, Yilmaz Esendagli G, Karahan S. Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2018;30:918-24. [PMID: 29683980 DOI: 10.1097/MEG.0000000000001123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
441 Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Borque MJ, López-Cabrera M, Moreno-Otero R. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology. 2005;42:696-701. [PMID: 16104024 DOI: 10.1002/hep.20828] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
442 Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep 2014;2:245-56. [PMID: 25396099 DOI: 10.1007/s40139-014-0061-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
443 Abdel-Hameed EA, Rouster SD, Kottilil S, Sherman KE. The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients. Clin Infect Dis 2021;73:450-9. [PMID: 32459305 DOI: 10.1093/cid/ciaa646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
444 Talwalkar JA. One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis. Hepatology 2009;50:1000-3. [PMID: 19787817 DOI: 10.1002/hep.23288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
445 Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, Peck-Radosavljevic M. Meta-analysis: ARFI elastography vs transient elastography for the evaluation of liver fibrosis. Liver Int. 2013;33:1138-1147. [PMID: 23859217 DOI: 10.1111/liv.12240] [Cited by in Crossref: 279] [Cited by in F6Publishing: 255] [Article Influence: 31.0] [Reference Citation Analysis]
446 Drescher HK, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 2019;8:E845. [PMID: 31394730 DOI: 10.3390/cells8080845] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
447 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 13.6] [Reference Citation Analysis]
448 Moreno-Sánchez D. [Epidemiology and natural history of primary nonalcoholic fatty liver disease]. Gastroenterol Hepatol 2006;29:244-54. [PMID: 16584696 DOI: 10.1157/13085972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
449 Chen C, Fu F, Zhang J, Guo F, Wang M, Zhu S, Shi D, Tian Y. Evaluation of liver fibrosis with a monoexponential model of intravoxel incoherent motion magnetic resonance imaging. Oncotarget 2018;9:24619-26. [PMID: 29872492 DOI: 10.18632/oncotarget.24758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
450 Yeung J, Ganeshan B, Endozo R, Hall A, Wan S, Groves A, Taylor SA, Bandula S. Equilibrium CT Texture Analysis for the Evaluation of Hepatic Fibrosis: Preliminary Evaluation against Histopathology and Extracellular Volume Fraction. J Pers Med 2020;10:E46. [PMID: 32485820 DOI: 10.3390/jpm10020046] [Reference Citation Analysis]
451 Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol 2009; 15(20): 2433-2440 [PMID: 19468990 DOI: 10.3748/wjg.15.2433] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
452 Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44:462-474. [PMID: 16427156 DOI: 10.1016/j.jhep.2005.10.019] [Cited by in Crossref: 169] [Cited by in F6Publishing: 162] [Article Influence: 9.9] [Reference Citation Analysis]
453 Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014;60:69-77. [PMID: 24036007 DOI: 10.1016/j.jhep.2013.09.002] [Cited by in Crossref: 239] [Cited by in F6Publishing: 208] [Article Influence: 26.6] [Reference Citation Analysis]
454 Mitsuka Y, Midorikawa Y, Abe H, Matsumoto N, Moriyama M, Haradome H, Sugitani M, Tsuji S, Takayama T. A prediction model for the grade of liver fibrosis using magnetic resonance elastography. BMC Gastroenterol 2017;17:133. [PMID: 29179678 DOI: 10.1186/s12876-017-0700-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
455 Connoley D, Patel PJ, Hogan B, Tanwar S, Rhodes F, Parkes J, Burt A, Watkins J, Sievert W, Rosenberg W. The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. BMC Gastroenterol 2021;21:268. [PMID: 34182924 DOI: 10.1186/s12876-021-01795-5] [Reference Citation Analysis]
456 Dhyani M, Xiang F, Li Q, Chen L, Li C, Bhan AK, Anthony B, Grajo JR, Samir AE. Ultrasound Shear Wave Elastography: Variations of Liver Fibrosis Assessment as a Function of Depth, Force and Distance from Central Axis of the Transducer with a Comparison of Different Systems. Ultrasound Med Biol 2018;44:2209-22. [PMID: 30143339 DOI: 10.1016/j.ultrasmedbio.2018.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
457 Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19 Suppl 1:18-32. [PMID: 22233410 DOI: 10.1111/j.1365-2893.2011.01518.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
458 Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comp Hepatol. 2012;11:5. [PMID: 23273224 DOI: 10.1186/1476-5926-11-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
459 Kim SU, Chon YE, Seo YS, Lee HW, Lee HA, Kim MN, Min IK, Park JY, Kim DY, Ahn SH, Tak WY, Kim BK, Park SY. A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy. J Viral Hepat 2020;27:1352-8. [DOI: 10.1111/jvh.13384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
460 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
461 Das SK, Vasudevan DM. Genesis of hepatic fibrosis and its biochemical markers. Scand J Clin Lab Invest. 2008;68:260-269. [PMID: 18609066 DOI: 10.1080/00365510701668516] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
462 Kang NL, Zhang JM, Lin MX, Chen XD, Huang ZX, Zhu YY, Liu YR, Zeng DW. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol 2020; 26(27): 3952-3962 [PMID: 32774069 DOI: 10.3748/wjg.v26.i27.3952] [Reference Citation Analysis]
463 Stefan N, Häring H, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The Lancet Diabetes & Endocrinology 2019;7:313-24. [DOI: 10.1016/s2213-8587(18)30154-2] [Cited by in Crossref: 220] [Cited by in F6Publishing: 115] [Article Influence: 73.3] [Reference Citation Analysis]
464 Morikawa H, Kawada N. Non-invasive diagnosis of liver fibrosis. Clin J Gastroenterol 2011;4:283-91. [DOI: 10.1007/s12328-011-0248-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
465 Sebastiani G, Halfon P, Castera L, Pol S, Thomas DL, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Guido M, Bourliere M, Noventa F, Alberti A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49:1821-1827. [PMID: 19291784 DOI: 10.1002/hep.22859] [Cited by in Crossref: 126] [Cited by in F6Publishing: 109] [Article Influence: 9.7] [Reference Citation Analysis]
466 Rocco A, de Nucci G, Valente G, Compare D, D’arienzo A, Cimino L, Perri F, Nardone G. 13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. Journal of Hepatology 2012;56:782-7. [DOI: 10.1016/j.jhep.2011.10.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
467 Guéchot J, Edrief S, Lasnier E, Küper R. Automated assay of hyaluronic acid in serum. Immuno-analyse & Biologie Spécialisée 2008;23:148-52. [DOI: 10.1016/j.immbio.2008.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
468 Hassan K, Bhalla V, Regal MEE, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20(34): 12082-12101 [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 95] [Article Influence: 13.8] [Reference Citation Analysis]
469 Kim BK, Kim HS, Park JY, Kim DY, Ahn SH, Chon CY, Park YN, Han KH, Kim SU. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7:e41964. [PMID: 22848675 DOI: 10.1371/journal.pone.0041964] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
470 Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, Hultcrantz R. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46:1111-1118. [PMID: 17399848 DOI: 10.1016/j.jhep.2007.01.024] [Cited by in Crossref: 142] [Cited by in F6Publishing: 120] [Article Influence: 9.5] [Reference Citation Analysis]
471 Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ;  Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104-1112. [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033] [Cited by in Crossref: 620] [Cited by in F6Publishing: 561] [Article Influence: 47.7] [Reference Citation Analysis]
472 Mölleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49:1257-1266. [PMID: 19177598 DOI: 10.1002/hep.22764] [Cited by in Crossref: 104] [Cited by in F6Publishing: 103] [Article Influence: 8.0] [Reference Citation Analysis]
473 de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104-S112. [PMID: 18304679 DOI: 10.1016/j.jhep.2008.01.009] [Cited by in Crossref: 358] [Cited by in F6Publishing: 349] [Article Influence: 25.6] [Reference Citation Analysis]
474 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
475 Zhu CL, Li WT, Li Y, Gao RT. Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. J Dig Dis. 2012;13:558-563. [PMID: 23107442 DOI: 10.1111/j.1751-2980.2012.00629.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
476 Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, Chen CW, Wang JY, Cai X, Gao CF, Zhou XQ. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology. 2005;42:1437-1445. [PMID: 16317674 DOI: 10.1002/hep.20960] [Cited by in Crossref: 111] [Cited by in F6Publishing: 114] [Article Influence: 6.5] [Reference Citation Analysis]
477 Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13(32): 4287-4294 [PMID: 17708599 DOI: 10.3748/wjg.v13.i32.4287] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
478 Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011;56:3038-44. [PMID: 21526398 DOI: 10.1007/s10620-011-1710-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
479 Eurich D, Boas-Knoop S, Struecker B, Neuhaus R, Neuhaus P, Bahra M. Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease. Transplantation. 2013;95:203-208. [PMID: 23202532 DOI: 10.1097/TP.0b013e318277e2f6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
480 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
481 Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775-782. [PMID: 17321634 DOI: 10.1016/j.jhep.2006.12.013] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 10.9] [Reference Citation Analysis]
482 Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One 2012;7:e47715. [PMID: 23082200 DOI: 10.1371/journal.pone.0047715] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
483 Lombardi R, Buzzetti E, Roccarina D, Tsochatzis EA. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World J Gastroenterol 2015; 21(39): 11044-11052 [PMID: 26494961 DOI: 10.3748/wjg.v21.i39.11044] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
484 Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. [PMID: 21849046 DOI: 10.1186/1471-230x-11-91] [Cited by in Crossref: 181] [Cited by in F6Publishing: 78] [Article Influence: 16.5] [Reference Citation Analysis]
485 Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, Byrne CD; WELCOME Trial Investigators. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected]. Contemp Clin Trials. 2014;37:301-311. [PMID: 24556343 DOI: 10.1016/j.cct.2014.02.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
486 Fossdal G, Mjelle AB, Wiencke K, Bjørk I, Gilja OH, Folseraas T, Karlsen TH, Rosenberg W, Giil LM, Vesterhus M. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. JHEP Rep 2021;3:100328. [PMID: 34485881 DOI: 10.1016/j.jhepr.2021.100328] [Reference Citation Analysis]
487 Ng VL, Mazariegos GV, Kelly B, Horslen S, Mcdiarmid SV, Magee JC, Loomes KM, Fischer RT, Sundaram SS, Lai JC, Te HS, Bucuvalas JC. Barriers to ideal outcomes after pediatric liver transplantation. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
488 Cortez-pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: From cell biology to clinical practice. Journal of Hepatology 2006;44:197-208. [DOI: 10.1016/j.jhep.2005.09.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 129] [Article Influence: 8.7] [Reference Citation Analysis]
489 Brennan PN, MacMillan M, Manship T, Moroni F, Glover A, Graham C, Semple S, Morris DM, Fraser AR, Pass C, McGowan NWA, Turner ML, Lachlan N, Dillon JF, Campbell JDM, Fallowfield JA, Forbes SJ. Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH). BMJ Open 2021;11:e053190. [PMID: 34750149 DOI: 10.1136/bmjopen-2021-053190] [Reference Citation Analysis]
490 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112. [PMID: 16447287 DOI: 10.1002/hep.20973] [Cited by in Crossref: 1618] [Cited by in F6Publishing: 1564] [Article Influence: 101.1] [Reference Citation Analysis]
491 Arulanandan A, Loomba R. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep 2015;14:109-18. [PMID: 26500833 DOI: 10.1007/s11901-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
492 Kekilli M, Tanoglu A, Sakin YS, Kurt M, Ocal S, Bagci S. Is the neutrophil to lymphocyte ratio associated with liver fibrosis in patients with chronic hepatitis B? World J Gastroenterol 2015; 21(18): 5575-5581 [PMID: 25987782 DOI: 10.3748/wjg.v21.i18.5575] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
493 Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, Portal I, Allemand I, Rosenthal-Allieri A. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol. 2005;4:6. [PMID: 16008833 DOI: 10.1186/1476-5926-4-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 92] [Article Influence: 5.2] [Reference Citation Analysis]
494 Saffioti F, Roccarina D, Vesterhus M, Hov JR, Rosenberg W, Pinzani M, Pereira SP, Boberg KM, Thorburn D. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis.Eur J Clin Invest. 2019;49:e13088. [PMID: 30762236 DOI: 10.1111/eci.13088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
495 Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401-9. [PMID: 20675691 DOI: 10.1136/gut.2010.207423] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 5.8] [Reference Citation Analysis]
496 Moreno S, García-Samaniego J, Moreno A, Ortega E, Pineda JA, del Romero J, Tural C, von Wichmann MA, Berenguer J, Castro A. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat. 2009;16:249-258. [PMID: 19215579 DOI: 10.1111/j.1365-2893.2009.01088.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
497 Gawrieh S, Wilson LA, Yates KP, Cummings OW, Vilar-Gomez E, Ajmera V, Kowdley KV, Rosenberg WM, Tonascia J, Chalasani N. Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. Hepatol Commun 2021;5:786-97. [PMID: 34027269 DOI: 10.1002/hep4.1680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
498 Peveler WJ, Algar WR. More Than a Light Switch: Engineering Unconventional Fluorescent Configurations for Biological Sensing. ACS Chem Biol 2018;13:1752-66. [DOI: 10.1021/acschembio.7b01022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
499 Busk TM, Bendtsen F, Nielsen HJ, Jensen V, Brünner N, Møller S. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scandinavian Journal of Gastroenterology 2014;49:1103-10. [DOI: 10.3109/00365521.2014.934910] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
500 Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH; Virahep-C Study Group. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006;44:925-35. [DOI: 10.1002/hep.21335] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
501 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007-1019. [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021] [Cited by in Crossref: 237] [Cited by in F6Publishing: 203] [Article Influence: 23.7] [Reference Citation Analysis]
502 Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008;28:503-22. [DOI: 10.1111/j.1365-2036.2008.03752.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
503 Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7:696-701. [PMID: 19514117 DOI: 10.1016/j.cgh.2009.01.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
504 Cross TJ, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. King's Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21:730-738. [PMID: 19430302 DOI: 10.1097/meg.0b013e32830dfcb3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
505 Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am. 2011;40:507-521. [PMID: 21893271 DOI: 10.1016/j.gtc.2011.06.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
506 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
507 Liu CC, Wang YH, Chuang EY, Tsai MH, Chuang YH, Lin CL, Liu CJ, Hsiao BY, Lin SM, Liu LY. Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers. Mol Carcinog. 2014;53:58-66. [PMID: 22911910 DOI: 10.1002/mc.21952] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
508 de Vries EM, Beuers U, Ponsioen CY. Biomarkers for disease progression of primary sclerosing cholangitis. Curr Opin Gastroenterol 2015;31:239-46. [PMID: 25695934 DOI: 10.1097/MOG.0000000000000163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
509 Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D, Sennett K, Morgan S, Tsochatzis EA, Rosenberg W. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71:371-378. [PMID: 30965069 DOI: 10.1016/j.jhep.2019.03.033] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 34.7] [Reference Citation Analysis]
510 Crespo G, Forns X, Navasa M. [Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation]. Gastroenterol Hepatol 2012;35 Suppl 2:17-22. [PMID: 23298655 DOI: 10.1016/S0210-5705(12)70045-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
511 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
512 Hydes T, Gilmore W, Sheron N, Gilmore I. Treating alcohol-related liver disease from a public health perspective. J Hepatol. 2019;70:223-236. [PMID: 30658724 DOI: 10.1016/j.jhep.2018.10.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
513 Shetty V, Jain P, Nickens Z, Sinnathamby G, Mehta A, Philip R. Investigation of plasma biomarkers in HIV-1/HCV mono- and coinfected individuals by multiplex iTRAQ quantitative proteomics. OMICS 2011;15:705-17. [PMID: 21978398 DOI: 10.1089/omi.2011.0004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
514 Mooney P, Hayes P, Smith K. The putative use of alpha-1-acid glycoprotein as a non-invasive marker of fibrosis. Biomed Chromatogr 2006;20:1351-8. [PMID: 17004233 DOI: 10.1002/bmc.704] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
515 Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, Smith C. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol. 2011;25:758-764. [PMID: 21198946 DOI: 10.1111/j.1468-3083.2010.03932.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
516 Bracht T, Schweinsberg V, Trippler M, Kohl M, Ahrens M, Padden J, Naboulsi W, Barkovits K, Megger DA, Eisenacher M, Borchers CH, Schlaak JF, Hoffmann A, Weber F, Baba HA, Meyer HE, Sitek B. Analysis of Disease-Associated Protein Expression Using Quantitative Proteomics—Fibulin-5 Is Expressed in Association with Hepatic Fibrosis. J Proteome Res 2015;14:2278-86. [DOI: 10.1021/acs.jproteome.5b00053] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
517 Cheng K, Mahato RI. Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst. 2007;24:93-146. [PMID: 17725523 DOI: 10.1615/critrevtherdrugcarriersyst.v24.i2.10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
518 Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight 2018;3:120274. [PMID: 30046009 DOI: 10.1172/jci.insight.120274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
519 Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005;42 Suppl:S22-S36. [PMID: 15777570 DOI: 10.1016/j.jhep.2004.12.008] [Cited by in Crossref: 163] [Cited by in F6Publishing: 147] [Article Influence: 9.1] [Reference Citation Analysis]
520 Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology 2018;154:1369-79. [DOI: 10.1053/j.gastro.2018.01.005] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 18.5] [Reference Citation Analysis]
521 Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47:789-798. [PMID: 18175357 DOI: 10.1002/hep.22099] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 9.1] [Reference Citation Analysis]
522 Kazankov K, Rosso C, Younes R, Armandi A, Hagström H, Møller HJ, Stål P, Bugianesi E, Grønbæk H. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. Front Med (Lausanne) 2020;7:616212. [PMID: 33392234 DOI: 10.3389/fmed.2020.616212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
523 López IC, Aroca FG, Bernal MDF, Mompeán JAL, Bernal ÁB, Martínez AMH, Barba EM, Velasco JAN, Paricio PP. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. Obes Surg 2017;27:2347-53. [PMID: 28229316 DOI: 10.1007/s11695-017-2606-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
524 Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, Mican JM, Suffredini A, Masur H, Polis MA, Kottilil S. Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS 2008;22:1433-9. [PMID: 18614866 DOI: 10.1097/QAD.0b013e328304dfe7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
525 He JS, Tan JY, Li XZ, Feng R, Xiong SS, Lin SN, Qiu Y, Mao R. Serum biomarkers of fibrostenotic Crohn's disease: Where are we now? J Dig Dis 2020;21:336-41. [PMID: 32496631 DOI: 10.1111/1751-2980.12913] [Reference Citation Analysis]
526 Han MAT. Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. Life (Basel) 2020;10:E198. [PMID: 32933184 DOI: 10.3390/life10090198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
527 Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int. 2006;26:1095-1099. [PMID: 17032410 DOI: 10.1111/j.1478-3231.2006.01356.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
528 Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, Loguercio C. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006;55:901-902. [PMID: 16698763 DOI: 10.1136/gut.2006.091967] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
529 Kim BK, Kim SA, Park YN, Cheong JY, Kim HS, Park JY, Cho SW, Han KH, Chon CY, Moon YM. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int. 2007;27:969-976. [PMID: 17696936 DOI: 10.1111/j.1478-3231.2007.01519.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
530 Lejealle C, Castera L. Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B. Curr Hepatology Rep 2018;17:492-501. [DOI: 10.1007/s11901-018-0439-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
531 Lai L, Chen J, Wei X, Huang M, Hu X, Yang R, Jiang X, Shan H. Transplantation of MSCs Overexpressing HGF into a Rat Model of Liver Fibrosis. Mol Imaging Biol 2016;18:43-51. [PMID: 26194009 DOI: 10.1007/s11307-015-0869-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
532 Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, D’Auria MV, Capasso R, Del Vecchio Blanco C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52:2387-2395. [PMID: 17410454 DOI: 10.1007/s10620-006-9703-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
533 Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Journal of Hepatology 2019;70:273-83. [DOI: 10.1016/j.jhep.2018.11.025] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 16.0] [Reference Citation Analysis]
534 Bansal MB, Friedman SL. Hepatic Fibrogenesis. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 94-102. [DOI: 10.1002/9781444341294.ch6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
535 Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut Liver 2013;7:323-8. [PMID: 23710314 DOI: 10.5009/gnl.2013.7.3.323] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
536 Gressner OA, Gao C. Monitoring fibrogenic progression in the liver. Clin Chim Acta. 2014;433:111-122. [PMID: 24607331 DOI: 10.1016/j.cca.2014.02.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
537 Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 2005;128:1146-8; author reply 1148. [PMID: 15825108 DOI: 10.1053/j.gastro.2005.02.056] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
538 Swanson S, Ma Y, Scherzer R, Huhn G, French AL, Plankey MW, Grunfeld C, Rosenberg WM, Peters MG, Tien PC. Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score. J Infect Dis 2016;213:1079-86. [PMID: 26621911 DOI: 10.1093/infdis/jiv567] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
539 Halfon P, Bourlière M, Pénaranda G, Cacoub P. Intérêt et limites des méthodes non invasives de prédiction de la fibrose hépatique au cours de l'hépatite C: une alternative à la biopsie hépatique. La Presse Médicale 2007;36:457-66. [DOI: 10.1016/j.lpm.2007.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
540 Luo Y, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, Collen R, Idowu M, Contos MJ, Mirshahi F, Daita K, Asgharpour A, Siddiqui MS, Jarai G, Rosen G, Christian R, Sanyal AJ. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Sci Rep. 2018;8:12414. [PMID: 30120271 DOI: 10.1038/s41598-018-30457-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
541 Czul F, Bhamidimarri KR. Noninvasive Markers to Assess Liver Fibrosis. J Clin Gastroenterol 2016;50:445-57. [PMID: 27105176 DOI: 10.1097/MCG.0000000000000534] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
542 Su CW, Chan CC, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Tsay SH, Lee PC, Lee SD. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol. 2009;43:876-883. [PMID: 19247208 DOI: 10.1097/mcg.0b013e31818980ac] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
543 Hauff P, Gottwald U, Ocker M. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opin Investig Drugs. 2015;24:309-327. [PMID: 25547844 DOI: 10.1517/13543784.2015.997874] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
544 de Vries EMG, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, Chazouillères O, Pares A, Nygård S, Gilja OH, Wunsch E, Invernizzi P, Carbone M, Bernuzzi F, Boberg KM, Røsjø H, Rosenberg W, Beuers UH, Ponsioen CY, Karlsen TH, Vesterhus M. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. Liver Int 2017;37:1554-61. [PMID: 28267887 DOI: 10.1111/liv.13402] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
545 Kim SU, Seo YS, Lee HA, Kim MN, Kim EH, Kim HY, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY. Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. Clin Gastroenterol Hepatol 2020; 18: 693-699. e1. [PMID: 31252188 DOI: 10.1016/j.cgh.2019.06.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
546 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1056/s0140-6736(08)60383-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
547 Posthouwer D, Fischer K, van Erpecum KJ, Mauser-Bunschoten EP. The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion. 2006;46:1360-1366. [PMID: 16934072 DOI: 10.1111/j.1537-2995.2006.00903.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
548 Selph SS, Ginsburg AD, Chou R. Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. Syst Rev 2014;3:107. [PMID: 25239493 DOI: 10.1186/2046-4053-3-107] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
549 Delvin E, Patey N, Dubois J, Henderson M, Lévy É. Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem 2015;34:3-12. [PMID: 28356817 DOI: 10.2478/jomb-2014-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
550 Marfà S, Crespo G, Reichenbach V, Forns X, Casals G, Morales-Ruiz M, Navasa M, Jiménez W. Lack of a 5.9 kDa peptide C-terminal fragment of fibrinogen α chain precedes fibrosis progression in patients with liver disease. PLoS One 2014;9:e109254. [PMID: 25275549 DOI: 10.1371/journal.pone.0109254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
551 Qi X, Liu X, Zhang Y, Hou Y, Ren L, Wu C, Chen J, Xia C, Zhao J, Wang D, Zhang Y, Zhang X, Lin H, Wang H, Wang J, Cui Z, Li X, Deng H, Hou F, Peng Y, Wang X, Shao X, Li H, Guo X. Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational Study. Med Sci Monit 2016;22:2720-30. [PMID: 27480906 DOI: 10.12659/msm.900441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
552 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
553 Cowan ML, Rahman TM, Krishna S. Proteomic approaches in the search for biomarkers of liver fibrosis. Trends Mol Med. 2010;16:171-183. [PMID: 20304704 DOI: 10.1016/j.molmed.2010.01.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
554 Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open. 2013;3:e003995. [PMID: 24189085 DOI: 10.1136/bmjopen-2013-003995] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
555 White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, Skehel M, Liu C, Zekry A, Cutler P. Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med. 2007;5:33. [PMID: 17625010 DOI: 10.1186/1479-5876-5-33] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
556 Miele L, De Michele T, Marrone G, Isgrò MA, Basile U, Cefalo C, Biolato M, Vecchio FM, Rapaccini GL, Gasbarrini A, Zuppi C, Grieco A. Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting. Int J Biol Markers 2017;32:397-402. [DOI: 10.5301/ijbm.5000292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
557 Lieber CS, Weiss DG, Paronetto F. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008;32:1031-1039. [PMID: 18422837 DOI: 10.1111/j.1530-0277.2008.00664.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
558 Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, Schulte S, Quasdorff M, Goeser T, Töx U, Steffen H. Stepwise Combination of Simple Noninvasive Fibrosis Scoring Systems Increases Diagnostic Accuracy in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2013;47:719-26. [DOI: 10.1097/mcg.0b013e3182819a89] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
559 Zhou IY, Catalano OA, Caravan P. Advances in functional and molecular MRI technologies in chronic liver diseases. J Hepatol 2020;73:1241-54. [PMID: 32585160 DOI: 10.1016/j.jhep.2020.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
560 Babaei Z, Parsian H. Hyaluronic acid algorithm-based models for assessment of liver fibrosis: translation from basic science to clinical application. Hepatobiliary Pancreat Dis Int 2016;15:131-40. [PMID: 27020628 DOI: 10.1016/s1499-3872(16)60062-0] [Reference Citation Analysis]
561 Xu J, Xia Y, Li S, Cheng X, Hu S, Gao Y, Zhou X, Wang G, Zheng Q. A retrospective pilot study to examine the potential of aspartate aminotransferase to alanine aminotransferase ratio as a predictor of postoperative acute kidney injury in patients with hepatocellular carcinoma. Ann Clin Biochem 2019;56:357-66. [PMID: 30453754 DOI: 10.1177/0004563218817797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
562 Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol. 2010;24:661-670. [PMID: 21157581 DOI: 10.1155/2010/153986] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
563 Wang C, Hann HW, Hann RS, Wan S, Myers RE, Ye Z, Xing J, Yang H. Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study. Dig Dis Sci 2015;60:1707-15. [PMID: 25588520 DOI: 10.1007/s10620-015-3523-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
564 Saha JK, Xia J, Sandusky GE, Chen YF, Gerlitz B, Grinnell B, Jakubowski JA. Study of plasma protein C and inflammatory pathways: biomarkers for dimethylnitrosamine-induced liver fibrosis in rats. Eur J Pharmacol. 2007;575:158-167. [PMID: 17719030 DOI: 10.1016/j.ejphar.2007.07.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
565 Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, Shahid I, Sumrin A, Khaliq S. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:44. [PMID: 21507271 DOI: 10.1186/1471-230x-11-44] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
566 Abu-Elsaad NM, Elkashef WF. Modified citrus pectin stops progression of liver fibrosis by inhibiting galectin-3 and inducing apoptosis of stellate cells. Can J Physiol Pharmacol. 2016;94:554-562. [PMID: 27010252 DOI: 10.1139/cjpp-2015-0284] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
567 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 29.8] [Reference Citation Analysis]
568 Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2008;103:928-936. [PMID: 18371145 DOI: 10.1111/j.1572-0241.2007.01761.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
569 Rieder F, de Bruyn JR, Pham BT, Katsanos K, Annese V, Higgins PD, Magro F, Dotan I. Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;8:1166-1178. [PMID: 24726695 DOI: 10.1016/j.crohns.2014.03.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
570 Ballengee CR, Stidham RW, Liu C, Kim MO, Prince J, Mondal K, Baldassano R, Dubinsky M, Markowitz J, Leleiko N, Hyams J, Denson L, Kugathasan S. Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2019;17:1799-806. [PMID: 30213581 DOI: 10.1016/j.cgh.2018.09.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
571 Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med. 2006;260:142-150. [PMID: 16882278 DOI: 10.1111/j.1365-2796.2006.01673.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
572 Lemoine M, Serfaty L. [Nonalcoholic fatty liver disease]. Presse Med 2012;41:169-89. [PMID: 21723084 DOI: 10.1016/j.lpm.2011.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
573 Zhu Y, Kruglikov IL, Akgul Y, Scherer PE. Hyaluronan in adipogenesis, adipose tissue physiology and systemic metabolism. Matrix Biol 2019;78-79:284-91. [PMID: 29458140 DOI: 10.1016/j.matbio.2018.02.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
574 Bota S, Sporea I, Sirli R, Popescu A, Danila M, Costachescu D. Intra- and Interoperator Reproducibility of Acoustic Radiation Force Impulse (ARFI) Elastography–Preliminary Results. Ultrasound in Medicine & Biology 2012;38:1103-8. [DOI: 10.1016/j.ultrasmedbio.2012.02.032] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
575 Bandula S, Punwani S, Rosenberg WM, Jalan R, Hall AR, Dhillon A, Moon JC, Taylor SA. Equilibrium Contrast-enhanced CT Imaging to Evaluate Hepatic Fibrosis: Initial Validation by Comparison with Histopathologic Sampling. Radiology 2015;275:136-43. [DOI: 10.1148/radiol.14141435] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
576 Welsh JA, Scorletti E, Clough GF, Englyst NA, Byrne CD. Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD. J Leukoc Biol 2018;104:631-9. [DOI: 10.1002/jlb.5a1217-501r] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
577 Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourlière M, de Muret A, Sturm N, Hunault G, Penaranda G. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem. 2008;41:1368-1376. [PMID: 18655779 DOI: 10.1016/j.clinbiochem.2008.06.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
578 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
579 Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008;48:606-613. [PMID: 18222014 DOI: 10.1016/j.jhep.2007.11.020] [Cited by in Crossref: 295] [Cited by in F6Publishing: 265] [Article Influence: 21.1] [Reference Citation Analysis]
580 Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB, Park YN. Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci. 2011;56:555-563. [PMID: 20585981 DOI: 10.1007/s10620-010-1305-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
581 Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013;57:103-111. [PMID: 22930399 DOI: 10.1002/hep.26030] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 8.1] [Reference Citation Analysis]
582 Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughan GW, Gorrell MD, Yue DK, Twigg SM. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol. 2011;55:435-444. [PMID: 21184785 DOI: 10.1016/j.jhep.2010.10.039] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
583 Cobbold JFL, Crossey MME, Colman P, Goldin RD, Murphy PS, Patel N, Fitzpatrick J, Vennart W, Thomas HC, Cox IJ, Taylor-robinson SD. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C: Biomarker combinations in hepatitis C. Journal of Viral Hepatitis 2010;17:537-45. [DOI: 10.1111/j.1365-2893.2009.01209.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
584 Sporea I, Şirli R, Popescu A, Bota S, Badea R, Lupşor M, Focşa M, Dănilă M. Is it better to use two elastographic methods for liver fibrosis assessment? World J Gastroenterol 2011; 17(33): 3824-3829 [PMID: 21987625 DOI: 10.3748/wjg.v17.i33.3824] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
585 Stojanovic M, Raskovic S, Milivojevic V, Miskovic R, Soldatovic I, Stankovic S, Rankovic I, Stankovic Stanojevic M, Dragasevic S, Krstic M, Diamantopoulos AP. Enhanced Liver Fibrosis Score as a Biomarker for Vascular Damage Assessment in Patients with Takayasu Arteritis-A Pilot Study. J Cardiovasc Dev Dis 2021;8:187. [PMID: 34940542 DOI: 10.3390/jcdd8120187] [Reference Citation Analysis]
586 Ahmed Y, Hussein RS, Basha TA, Khalifa AM, Ibrahim AS, Abdelmoaty AS, Abdella HM, Fahmy AS. Detecting liver fibrosis using a machine learning-based approach to the quantification of the heart-induced deformation in tagged MR images. NMR Biomed. 2020;33:e4215. [PMID: 31730265 DOI: 10.1002/nbm.4215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
587 Elsharkawy A, Alem SA, Fouad R, El Raziky M, El Akel W, Abdo M, Tantawi O, AbdAllah M, Bourliere M, Esmat G. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol 2017;32:1624-30. [PMID: 28177543 DOI: 10.1111/jgh.13758] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
588 Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed? Journal of Hepatology 2005;42:12-4. [DOI: 10.1016/j.jhep.2004.11.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
589 Palaniyappan N, Cox E, Bradley C, Scott R, Austin A, O'Neill R, Ramjas G, Travis S, White H, Singh R, Thurley P, Guha IN, Francis S, Aithal GP. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. J Hepatol. 2016;65:1131-1139. [PMID: 27475617 DOI: 10.1016/j.jhep.2016.07.021] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
590 Ladero JM. Noninvasive evaluation of liver fibrosis in patients with chronic hepatitis C. Hepat Mon 2011;11:698-700. [PMID: 22235211 DOI: 10.5812/kowsar.1735143X.738] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
591 Moon KM, Kim G, Baik SK, Choi E, Kim MY, Kim HA, Cho MY, Shin SY, Kim JM, Park HJ, Kwon SO, Eom YW. Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. Clin Mol Hepatol 2013;19:389-98. [PMID: 24459644 DOI: 10.3350/cmh.2013.19.4.389] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
592 Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne) 2021;8:615978. [PMID: 33937277 DOI: 10.3389/fmed.2021.615978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
593 Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, Afendy A, Younoszai Z, Goodman Z, Baranova A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg. 2011;21:431-439. [PMID: 20532833 DOI: 10.1007/s11695-010-0204-1] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 9.5] [Reference Citation Analysis]
594 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. In: Hamdy Gad E, editor. Nonalcoholic Fatty Liver Disease - An Update. IntechOpen; 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Lizaola B, Bonder A, Tapper EB, Afdhal N. Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. Curr Hepatology Rep 2016;15:220-9. [DOI: 10.1007/s11901-016-0311-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
596 Saludes V, González V, Planas R, Matas L, Ausina V, Martró E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol 2014; 20(13): 3431-3442 [PMID: 24707126 DOI: 10.3748/wjg.v20.i13.3431] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
597 Carrión JA, Fernández-Varo G, Bruguera M, García-Pagán JC, García-Valdecasas JC, Pérez-Del-Pulgar S, Forns X, Jiménez W, Navasa M. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology. 2010;138:147-158.e1. [PMID: 19786026 DOI: 10.1053/j.gastro.2009.09.047] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
598 Heise RL, Stober V, Cheluvaraju C, Hollingsworth JW, Garantziotis S. Mechanical stretch induces epithelial-mesenchymal transition in alveolar epithelia via hyaluronan activation of innate immunity. J Biol Chem 2011;286:17435-44. [PMID: 21398522 DOI: 10.1074/jbc.M110.137273] [Cited by in Crossref: 80] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
599 Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: REVIEW: CURRENT MANAGEMENT OF NAFLD AND NASH. Alimentary Pharmacology & Therapeutics 2008;28:2-12. [DOI: 10.1111/j.1365-2036.2008.03710.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 7.2] [Reference Citation Analysis]
600 Rath T, Hage L, Kügler M, Menendez Menendez K, Zachoval R, Naehrlich L, Schulz R, Roderfeld M, Roeb E. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One. 2013;8:e58955. [PMID: 23516586 DOI: 10.1371/journal.pone.0058955] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
601 Zeng DW, Liu YR, Zhang JM, Zhu YY, Lin S, You J, Li YB, Chen J, Zheng Q, Jiang JJ, Dong J. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One. 2013;8:e77942. [PMID: 24282481 DOI: 10.1371/journal.pone.0077942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
602 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
603 Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016;64:308-315. [PMID: 26471505 DOI: 10.1016/j.jhep.2015.10.009] [Cited by in Crossref: 116] [Cited by in F6Publishing: 105] [Article Influence: 16.6] [Reference Citation Analysis]
604 Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013;59:236-242. [PMID: 23523583 DOI: 10.1016/j.jhep.2013.03.016] [Cited by in Crossref: 157] [Cited by in F6Publishing: 135] [Article Influence: 17.4] [Reference Citation Analysis]
605 Zhang Z, Li J, Wang P, He T, Ouyang Y, Huang Y. Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis. Sci Rep 2017;7:17493. [PMID: 29235488 DOI: 10.1038/s41598-017-17685-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
606 Sagnelli C, Martini S, Pisaturo M, Pasquale G, Macera M, Zampino R, Coppola N, Sagnelli E. Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World J Hepatol 2015; 7(24): 2510-2521 [PMID: 26523204 DOI: 10.4254/wjh.v7.i24.2510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
607 Nagelkerke SCJ, Draijer LG, Benninga MA, Koot BGP, Tabbers MM. The prevalence of liver fibrosis according to non-invasive tools in a pediatric home parenteral nutrition cohort. Clin Nutr 2021;40:460-6. [PMID: 32636112 DOI: 10.1016/j.clnu.2020.05.039] [Reference Citation Analysis]
608 Alhinai A, Patel K, Fonseca VA, Sebastiani G. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications 2021;35:107978. [PMID: 34183247 DOI: 10.1016/j.jdiacomp.2021.107978] [Reference Citation Analysis]
609 Bhogal H, Sterling RK. Staging of liver disease: which option is right for my patient? Infect Dis Clin North Am. 2012;26:849-861. [PMID: 23083819 DOI: 10.1016/j.idc.2012.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
610 Pilz S, Putz-Bankuti C, Gaksch M, Spindelboeck W, Haselberger M, Rainer F, Posch A, Kreuzer P, Stojakovic T, Stadlbauer V, Obermayer-Pietsch B, Stauber RE. Effects of Vitamin D Supplementation on Serum 25-Hydroxyvitamin D Concentrations in Cirrhotic Patients: A Randomized Controlled Trial. Nutrients 2016;8:E278. [PMID: 27171112 DOI: 10.3390/nu8050278] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
611 Wang M, Liu R, Liang Y, Yang G, Huang Y, Yu C, Sun K, Lai Y, Xia Y. Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patients. United European Gastroenterol J 2017;5:94-103. [PMID: 28405327 DOI: 10.1177/2050640616646525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
612 Armstrong MJ, Corbett C, Hodson J, Marwah N, Parker R, Houlihan DD, Rowe IA, Hazlehurst JM, Brown R, Hübscher SG. Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice. Postgrad Med J. 2013;89:685-692. [PMID: 23924687 DOI: 10.1136/postgradmedj-2012-131640] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
613 Loo WM, Goh GB, Wang Y, Yuan JM, Ong L, Dan YY, Koh WP. Enhanced Liver Fibrosis Score as a Predictor of Hepatocellular Carcinoma. Clin Chem 2018;64:1404-5. [PMID: 29941470 DOI: 10.1373/clinchem.2018.289108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
614 Drasar E, Fitzpatrick E, Gardner K, Awogbade M, Dhawan A, Bomford A, Suddle A, Thein SL. Interim assessment of liver damage in patients with sickle cell disease using new non-invasive techniques. Br J Haematol 2017;176:643-50. [PMID: 27984631 DOI: 10.1111/bjh.14462] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
615 Houlihan DD, Newsome PN. Critical Review of Clinical Trials of Bone Marrow Stem Cells in Liver Disease. Gastroenterology 2008;135:438-50. [DOI: 10.1053/j.gastro.2008.05.040] [Cited by in Crossref: 137] [Cited by in F6Publishing: 118] [Article Influence: 9.8] [Reference Citation Analysis]
616 Mansoor S, Collyer E, Alkhouri N. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic Fatty liver disease. Curr Gastroenterol Rep. 2015;17:23. [PMID: 26031832 DOI: 10.1007/s11894-015-0447-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
617 Gressner AM, Rizk M, Gao C, Gressner OA. Potential novel biomarkers for monitoring the fibrogenic process in liver. Arab Journal of Gastroenterology 2010;10:S12-6. [DOI: 10.1016/j.ajg.2009.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
618 Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 2006; 12(21): 3338-3343 [PMID: 16733849 DOI: 10.3748/wjg.v12.i21.3338] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
619 Pacana T, Sanyal AJ. Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep. 2015;7:28. [PMID: 25926979 DOI: 10.12703/p7-28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
620 Nielsen J, Christensen VB, Borgwardt L, Rasmussen A, Østrup O, Kjær MS. Prognostic molecular markers in pediatric liver disease – Are there any? Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:577-86. [DOI: 10.1016/j.bbadis.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
621 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
622 Nishikawa H, Hasegawa K, Ishii A, Takata R, Enomoto H, Yoh K, Kishino K, Shimono Y, Iwata Y, Nakano C, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) 2016;95:e4679. [PMID: 27583895 DOI: 10.1097/MD.0000000000004679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
623 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 310] [Cited by in F6Publishing: 296] [Article Influence: 103.3] [Reference Citation Analysis]
624 Calès P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32:40-51. [PMID: 18973845 DOI: 10.1016/s0399-8320(08)73992-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
625 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20(32): 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
626 Kehlet SN, Willumsen N, Armbrecht G, Dietzel R, Brix S, Henriksen K, Karsdal MA. Age-related collagen turnover of the interstitial matrix and basement membrane: Implications of age- and sex-dependent remodeling of the extracellular matrix. PLoS One 2018;13:e0194458. [PMID: 29596429 DOI: 10.1371/journal.pone.0194458] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
627 Dellavance A, Fernandes F, Shimabokuro N, Latini F, Baldo D, Barreto JA, Marvulle V, Andrade LE, Ferraz ML. Enhanced liver fibrosis (ELF) score: Analytical performance and distribution range in a large cohort of blood donors. Clinica Chimica Acta 2016;461:151-5. [DOI: 10.1016/j.cca.2016.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
628 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9] [Cited by in Crossref: 1212] [Cited by in F6Publishing: 538] [Article Influence: 86.6] [Reference Citation Analysis]
629 Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11): 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i11.2854] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
630 Yosry A, Fouad R, Alem SA, Elsharkawy A, El-sayed M, Asem N, Hassan E, Ismail A, Esmat G. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab Journal of Gastroenterology 2016;17:78-83. [DOI: 10.1016/j.ajg.2016.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
631 Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55:1650-60. [PMID: 17047111 DOI: 10.1136/gut.2006.091454] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 5.6] [Reference Citation Analysis]
632 Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, Del Galdo F. The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Ann Rheum Dis 2013;73:420-7. [DOI: 10.1136/annrheumdis-2012-202843] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
633 Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:541-552. [PMID: 19072402 DOI: 10.1586/17474124.2.4.541] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
634 Sterling RK, Lyons CD, Stravitz RT, Luketic VA, Sanyal AJ, Carr ME, Smith TJ, Hackney MH, Contos MJ, Mills SA, Kuhn JG, Nolte ME, Shiffman ML. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia 2007;13:164-71. [DOI: 10.1111/j.1365-2516.2006.01322.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
635 Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010;10:103. [PMID: 20828377 DOI: 10.1186/1471-230x-10-103] [Cited by in Crossref: 83] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
636 Carrión JA. Utilidad del Fibroscan® para evaluar la fibrosis hepática. Gastroenterología y Hepatología 2009;32:415-23. [DOI: 10.1016/j.gastrohep.2009.01.178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]